annual report sustainable innovation core innovation core everything committed transform lives pushing boundaries pursue groundbreaking solutions across functions patients need next look ahead create healthy stable future people planet pharmaceuticals diagnostics one roof uniquely positioned improve care along patient journey investing cuttingedge research collaborative partnerships continue transform ideas lifechanging solutions people communities worldwide contents letters shareholders sustainability report contribute corporate governance remuneration reportannual report roche contents letters shareholders sustainability report contribute corporate governance remuneration report rochecomreporting contents letters shareholders sustainability report contribute corporate governance remuneration reportletters shareholders roche letters shareholders contents letters shareholders sustainability report contribute corporate governance remuneration report dr severin schwanchairmans shareholder letter roche dear shareholders roche year marked significant opportunities make work even efficient management changes pleased along entire value chain includes successor ceo thomas schinecker instance testing developing new methods leadership team already embarked series research development important initiatives roche characterised ability combine continuity change one great example foundation remain committed values strategy institute human biology ihb basel last year time evolve organisation institute focused among things initiate necessary changes accordingly research organoids miniature models organs tissues grown laboratory convinced strategy used researching diseases without focused innovation pharmaceuticals rely real organs also means reduce diagnostics ensures remain strong position animal testing even accelerating consistent ability successfully bring new improving development much needed products patients hallmark company innovative treatments particularly last year able offset expected significant decline covid important innovative strength business new products large proportion innovation takes place outside company reason securing even ability innovate remain key success longterm partnerships academic institutions factor roche future need hospitals companies remains essential courage take risks industry part strategy example recent handful molecules make leap acquisition telavant provides opportunity development approved medicine roche us combat various autoimmune diseases exception also overcome promising new mechanism action setbacks recent times acquisition carmot able tap new compound alzheimers patients potential new medicines obesity heart endeavours metabolic diseases exactly motivates us keep creating better framework order maintain foster innovation sustainable strengthen creativity innovative spirit reaches patients need one roche starts companys culture key priorities therefore remains facilitate incredibly talented people work improve worldwide access medicines yet time must keep looking diagnostic tests contents letters shareholders sustainability report contribute corporate governance remuneration report roche board directors december dr severin schwan chairman e andr hoffmann vicechairman representative shareholder group pooled voting rights c e g dr jrg duschmal representative shareholder group pooled voting rights b c e g dr patrick frost b e g anita hauser c e g prof dr akiko iwasaki e g prof dr richard p lifton c e g dr jemilah mahmood e g bernard poussot c e g dr mark schneider b e g dr claudia suessmuth dyckerhoff b e g corporate governance sustainability committee b audit committee c remuneration committee chairmansnomination committee e nonexecutive director f executive director currently member g independent member board directors committee chairpersonchairmans shareholder letter roche results perspective good receive medicines diagnostic tests year roche spite expected decline employees devote achieving sales covid products chf billion goal great passion dedication every total sales rose constant exchange rates single day would like thank ifrs net income came chf billion tireless efforts board directors therefore proposes thank dear shareholders placing annual general meeting increase dividend trust us chf per share approved th consecutive increase lastly past year also marked geopolitical uncertainties major conflicts war terror dreadful impact events affected situations becomes even dr severin schwan important ensure patients continue chairman unless otherwise stated growth rates comparisons previous year constant exchange rates cer average rates total figures quoted reported chf contents letters shareholders sustainability report contribute corporate governance remuneration report dr thomas schineckershareholder letter ceo roche group roche dear shareholders demanding successful year also achieved important roche strong business performance milestones patients innovative promising medical advances key partnerships immunotherapies columvi lunsumio acquisitions bispecific antibodies aimed activating bodys immune system opened new avenues also year world health combat blood cancer columvi shown organization declared end coronavirus promising results people aggressive form pandemic roche proud significant blood cancer already received several contributions made towards achieving treatments urgent need new options objective lunsumio offers new promise patients special type follicular lymphoma disease return normality consequently led progresses slowly incurable decline covid sales given annual result impressive sales positive phase iii data alecensa chf billion increase constant inavolisib lung breast cancer respectively exchange rates offset decline highlights alecensa already covid sales impact biosimilargeneric effective specific form advanced lung erosion overall able compensate cancer offers chance cure chf billion early stages disease inavolisib could sales success rooted strong base prove medical breakthrough form business without covid products grew advanced hardtotreat breast cancer thanks high demand newer diagnostics medicines roche long tradition complementing research development activities one particular highlight vabysmo innovative external partnerships different medicine treatment eye diseases partnering alnylam gained access lead blindness around million people investigational therapeutic treating high blood worldwide currently suffer wet agerelated pressure disease affects billion people macular degeneration diabetic macular oedema adequately controlled retinal vein occlusion many elderly people treatments currently available telavant vabysmo already offers new hope may help acquired potential treatment inflammatory maintain even regain eyesight bowel disease immunemediated thus independence vabysmo made significant diseases addition acquisition carmot contribution companys growth potential enrich portfolio one successful product range programmes obesity launches roches history metabolic disorders unless otherwise stated growth rates comparisons previous year constant exchange rates cer average rates total figures quoted reported chf biosimilarsgenerics avastin herceptin mabtherarituxan lucentis esbriet contents letters shareholders sustainability report contribute corporate governance remuneration report roche corporate executive committee december dr thomas schinecker ceo roche group teresa graham ceo roche pharmaceuticals matt sause ceo roche diagnostics dr alan hippe chief financial information officer cristina wilbur chief people officer claudia bckstiegel general counsel prof dr hans clevers head roche pharma research early development pred dr levi garraway head global product development chief medical officer silke hrnstein head corporate strategy sustainability dr aviv regev head genentech research early development gred dr james h sabry global head pharma partnering barbara schdler head group communications member enlarged corporate executive committeeshareholder letter ceo roche group roche wellknown treat mission honoured part know patient care always begins diagnosis team years second innovation remains importance immense modern diagnostics core company past ten years pivotal early detection diseases brought new medicines targeted treatments example infection patients thus successfully diversified related conditions sepsis often called portfolio today leading cancer blood poisoning sepsis leading cause treatments also neuroscience ophthalmology death newborns elecsys il worlds haemophilia also market leader first immunoassay diagnosis sepsis invitro diagnostics newborns setting new standard fight severe condition order keep delivering innovative medicines diagnostics clear researchdriven early diagnosis treatment monitoring also companies like roche must continue push crucial neurological diseases roche scientific frontiers made significant progress area example elecsys nfl test obtained breakthrough device therefore personal focus first designation fda minimally invasive months ceo work teams test helps detect disease activity certain forms find ways strengthen pipeline multiple sclerosis could therefore support ability innovate together laid better disease management foundation future one example digitalisation includes increased use also launched navify algorithm suite artificial intelligence stages drug digital library medical algorithms help development process improve clinical decisionmaking combination different data points library strengthening research development already enabling better diagnoses cardiology engine also forms basis increasing value oncology continuously expanded company roche pharmaceuticals diagnostics digital solutions one roof achieved lot would like thank uniquely positioned continue develop employees worldwide breakthrough innovations patients around outstanding commitment improving world patients lives would like thank everyone worked us also marks first year ceo roche improve lives patients thank time full exciting new challenges valued shareholders trust opportunities months many placed company indepth extensive rewarding conversations colleagues customers patients stakeholders listen learn conversations two important insights reaffirmed first roche work fantastic dr thomas schinecker people passionate company ceo roche group contents letters shareholders sustainability report contribute corporate governance remuneration reportsustainability report roche sustainability report approach sustainability purpose strategy business model business performance roche group diagnostics pharmaceuticals reporting approach key sustainability topics partnering patients access healthcare diversity equity inclusion safety health wellbeing ethical business practices human rights environment global citizenship information security independent practitioners limited assurance report contents letters shareholders sustainability report contribute corporate governance remuneration report approach sustainability purpose patients need next identify meet needs every day must sustainable succeed sustainability built business strategy longer better productive lives enabling part everyones job roche engage support contribute regularly systematically internal local economies external stakeholders understand needs build mutual trust holistic approach commitments initiatives sustainability integrates three dimensions roche dedicated working partners across beyond sector amplify collective society contribute better society social environmental impact committed developing new medicines ways diagnosing several global sustainability initiatives including disease provide lifechanging benefits united nations sustainable development patients deep respect human goals rights everyone reach especially patients roche contributes number united business partners suppliers local communities nations sustainable development goals sdgs course colleagues around world specific targets within sphere emphasise employee safety health work particularly important role development promoting diversity play contributing sdg good health equity inclusion integrity mutual respect wellbeing associated targets good equal opportunities health plays foundational role supporting strong societal economic development environment respect healthy planet united nations global compact environment always priority roche signatory united company committed halving nations global compact ungc since environmental impact operations communication progress cop confirms products aim reduce commitment integrating ungc greenhouse gas emissions absolute principles human rights labour environment zero partnering suppliers anticorruption across strategy culture reduce emissions mutual benefit daytoday operations advancing global development goals particular economy business must meet needs united nations sdgs patients continue creating quality jobs science based targets initiative provide people families secure roche committed science based livelihoods earning competitive returns targets initiative sbti achieve absolute net investors promoting innovation zero scope greenhouse gas translating science pioneering emissions sbti drives necessary climate medicines diagnostics help patients live action private sector enablingour approach sustainability roche sustainability built business strategy part everyones job roche contents letters shareholders sustainability report contribute corporate governance remuneration report organisations set sciencebased emissions reporting internal external risks reduction targets sbti partnership opportunities consolidated group risk report carbon disclosure project cdp covering material risks opportunities ungc world resources institute wri discussed corporate executive committee world wide fund nature wwf reviewed board directors annually emissions reduction guidance businesses effectiveness roches group risk become recognised globally gold standard management process regularly monitored sustainable markets initiative smi group risk advisory team overall process roche joined smi health systems task reviewed audit committee board force address emissions across supply directors also externally appropriate chains patient care pathways clinical trials risk management embedded levels smi health systems task force launched roche group pharmaceuticals diagnostics th united nations climate change divisions global functions conduct formal risk conference cop central aim opportunity assessment least year accelerating delivery netzero patient must develop response plans centric healthcare systems improve individual material risks opportunities societal planetary health publicprivate partnership brings together ceos leaders read corporate governance astrazeneca gsk merck novo nordisk roche samsung biologics sanofi karolinska also identify longterm business environment institutet national health service england trends associated risks opportunities sustainable healthcare coalition unicef annual basis integrate university pavia group risk management process year pharmaceutical supply chain initiative emerging trends identified internal roche member pharmaceutical supply external sources sustainability steering chain initiative psci collaboration committee evaluates selects trends pharmaceutical companies suppliers associated risks opportunities shared vision establish promote relevant roche responsible business practices continuously improve human rights ethics labour health sustainability risks opportunities focus safety environmentally sustainable outcomes also established diligent business pharmaceutical supply chains psci sustainability risk opportunity assessment principles process identify assess mitigate significant social environmental economic risks risk assessment management process opportunities could impact business risk management policy sets roches objectives protect interests approach identifying analysing managing stakeholders long term gorochecomriskmanagementpolicyour approach sustainability roche widespread increase chronic physical climate action failure environmental mental health conditions infectious diseases degradation increasing biodiversity loss continuous emerging threats physical mental extreme weather events ecosystem collapses aggravated wellbeing leads rising costs health systems climate action failure threaten stability physical threatening societal gains life expectancy quality business environment wellbeing stakeholders political complexity progressing cyberdependency geoeconomic confrontations vulnerability state collapse armed conflict regional mounting cyberdependency due global instability shifting political influence everincreasing digital interconnectedness unstable political relationships add everyone everything lead complexity business environment overreliance creating vulnerabilities business societal crises lasting economic instability environment societal models limited educational lasting global macroeconomic instability economic prospects threaten societal trends leading potential collapse systemically solidarity causing regional instabilities important industries creates undercurrent disrupting interconnected global markets uncertainty across business world mistrust scepticism science future work wide persistent spread false information companies must experiment agile deliberate unintended states populists organisational design new ways working media instil mistrust even accommodate increasingly virtual business advanced science knowledge world changing workforce demands healthcare evolution challenged affordability accelerated technological transformation healthcare evolves towards continuumofcare approach rapid technological transformation continues expand offering full range solutions prevention opportunities across sectors pace change detection cure fair value proves challenging increases unpredictability implications business contents letters shareholders sustainability report contribute corporate governance remuneration report social environmental economic risks opportunities risk description actions climate witness effects climate change grow frequency intensity roche committed set near longterm companywide emission change implications business environment become increasingly clear reductions line sciencebased net zero science based targets extreme unpredictable weather events disrupt company operations initiative sbti local communities urgent need climate action changing demands expectations business stakeholders worldwide based ambitious emissions reduction trajectory outperform implications climate change global health nature spread intergovernmental panel climate change ipcc scenarios limit disease particularly important healthfocused organisations global warming c without offsetting emissions ensure continue path sites required develop roadmaps towards roche approaches issue climate change double materiality sustainable energy future tangible actions achieve real zero emissions perspective acknowledging impact climate change without offsetting influence climate change business assess climate changerelated risk implications business guides assessing climate changerelated risks committed disclosing decisionmaking process enables us develop proactive mitigation updated tcfd report strategies enhance resilience greenhouse un climate change conference parties signed legally majority ghg emissions originate transformation gas emissions binding international treaty climate change ie paris agreement use energy aim reduce emissions reducing energy parties committed reducing greenhouse gas ghg consumption switching entirely sustainable energy favour emissions limit effects global warming since conference use carbon offsetting alternative reducing emissions countries around world advanced action legislation focusing emissions reduction substitution nonsustainable ghg emissions reduction making priority companies energy rather offsetting aim achieve real zero emissions guided european green deal european nations companies set action plans across sites reduce ghg emissions leaders energy transition away fossil fuels result involves implementation innovative technologies continuous combined factors increasingly visible effects upgrading infrastructure climate change stakeholders demanding emissions reduction results us peers use energyefficient equipment continue evaluate employees travel needs set goal ghg emissionsfree vehicle fleet mitigate risks committed maintaining low levels ghg emissions business therefore production continues grow also change work processes complex task highly regulated ambitious goal eliminate ghg emissions operations approved facilities focusing effects steady energy purchases transition use sustainable energy phasing fossil fuel use substitute energies sustainable sources corruption corrupt business behaviour bribery unfair advantages theft roche employees businesscritical business partners complete fraud embezzlement misuse company assets persistent todays mandatory elearning compliance covers bribery improper interconnected increasingly competitive world failure actively advantages gifts entertainment conflict interest discrimination manage threat legal financial implications also harms harassment responsible use social media electronic communication companies reputation jeopardises licence operate tools business partners supply chain employees must complete compliance training join roche undergo periodic refreshers given broad scope roche operations worldwide different including whenever roche group code conduct updated types relationships key stakeholders exposure corruption risk reject forms corrupt business behaviour anyone becomes aware potential violation roche group code key expectations regarding integrity communicated roche conduct encouraged bring attention compliance experts roche group code conduct behaviour business directive outlines takes reports noncompliance seriously fully committed efficiently approach anticorruption antibribery timely investigate facts take necessary corrective action environmental goals rochecomaboutsustainabilityenvironmentgoalsperformance task force climaterelated financial disclosures gorochecomclimateriskmanagement roche group code conduct rochecomaboutgovernancecodeofconduct behaviour business gorochecombehaviourinbusinessour approach sustainability roche social environmental economic risks opportunities continued risk description actions human rights globalised world business value chains often span across international roche upholds human rights principles across operations borders giving millions people opportunity participate global value chain policies place well risk management economy however also brings challenges ensuring workers human approach mitigate prevent infringement human rights rights part roches global operations employees adverse impacts including assessment whether reasonable thousands business partners risk involved grounds suspect child labour negative human rights impacts conducted group human rights risk assessment operations thirdparty operations operations assessment identified data privacy access healthcare fair safe work environment focus areas supply chain working conditions fair treatment nondiscrimination healthy work environment identified focus areas talent ability create inclusive work environment people diverse introduced strategic workforce planning identify skills attraction backgrounds experiences skills ideas essential innovation needed future prepare attract develop employees development based company roche risk well could mean skill sets retention unable attract retain talented people innovation capabilities need deliver ambitions especially case global employee opinion survey geos conducted every two years face increasing skills shortage environment growing helps us understand employee perceptions sentiments competition existing new players geographies adapting work roche navigate new agile virtual ways working requires conduct organisationwide pay equity analysis every three years iterative talent strategies new skills differentiated leadership focus also conducted livingwage analysis repeat wellbeing continuously monitor progress towards workforce periodically future goals refine approach strengthen talent pipeline offer information programmes support physical mental health wellbeing employees oneroche learning development portfolio enables employees access training development options become lifelong learners leadership commitments set clear expectations people leaders roche series programmes symbiosis designed continually build leadership capability several programmes available help managers lead virtual diverse global teams information human rights see information dei activities see careersrochecomglobalendiversityequityinclusion roche group employment policy gorochecomgroupemploymentpolicy annual report reference living wage rochecomarepdf information wellbeing see careersrochecomglobalenyourwellbeingmatters leadership commitments gorochecomgroupemploymentpolicy sustainability aspects identified found section report kpis material roche drive greater impact reassessed regularly ensure company defined key performance relevant measure effectiveness indicators kpis allow us measure progress actions implemented defined topic meet actions implemented relevant data points regulatory transparency requirements contents letters shareholders sustainability report contribute corporate governance remuneration report purpose believe urgent deliver medical solutions right even develop innovations future passionate transforming patients lives courageous decision action believe good business means better world come work day commit scientific rigour unassailable ethics access medical innovations today build better tomorrow proud many working one across functions across companies across world rocheour purpose roche patients need next contents letters shareholders sustainability report contribute corporate governance remuneration report strategy business model focus finding new medicines diagnostics many different stakeholders healthcare establishing databased insights evolve ecosystem broaden access offerings practice medicine help patients live people need ultimately longer better lives provide seamless patient journey continue concentrate energies business environment undergoing prescription medicines vitro diagnostics tremendous change facing new challenges increasingly data insights rather due complexity care increasing diversify sectors like generics pressure healthcare budgets biosimilars overthecounter medicines time see new opportunities arising major advances life sciences digitalisation delivery create value healthcare stakeholders partner choice bringing significant medical benefit patients doctors turbulent times guided payers offering great place work common purpose patients employees delivering sustainable positive need next company bringing novel contribution society earning competitive diagnostics treatments patients returns investors years patients remain core reason come work every day ultimately delivering commitments takes people integrity courage passion making difference patients people focus vision fitting treatments proud say roche patients providing right therapy right patient ensure best response right leadership inspires outcomes matter time right value approach combines embracing diversity equity inclusion different rich expertise pharmaceuticals diagnostics backgrounds perspectives experiences expanded data science capabilities drive across entire organisation foster innovative effective efficient research solutions benefit patients ways enable better therapeutic decisions patients working enable agile networked responses everincreasing pace change balancing pursuit excellence science rests four needs stability speed flexibility key elements exceptionally broad deep understanding disease biology seamless setup designed innovation integration capabilities pharmaceuticals autonomous research development centres diagnostics diversity approaches alliances external partners maximise innovation longterm orientation foster diversity scientific approaches agility global geographical scale reach working partnership third parties enables us attract talent leading global offer integrated solutions improved medical science clusters quickly bring solutions health economic benefits work people need themour strategy business model roche business model management model focus leadership fitting treatments patients inspiring outcomes matter distinctiveness ways working excellence science agile networked delivery setup value stakeholders built innovation contents letters shareholders sustainability report contribute corporate governance remuneration report business performance demanding successful year roche good results base business able offset sharp yet expected drop covid sales diagnostics base business newer medicines continued show strong growth diagnostics division strength especially excited good progress portfolio combined commercial product pipeline notably oncology excellence affiliates resulted strong ophthalmology neurology additionally base business growth forged important partnerships collaborations acquisitions areas high pharmaceuticals division experienced unmet need impressive growth thanks advanced medicines like vabysmo severe eye diseases innovation continue companys core ocrevus multiple sclerosis hemlibra strong product portfolio divisions haemophilia polivy blood cancer promising product pipeline roche well phesgo breast cancer positioned future growthbusiness performance roche seamless integration capabilities roche pharmaceuticals roche diagnostics uniquely positioned achieve medical breakthroughs patients society contents letters shareholders sustainability report contribute corporate governance remuneration report roche group roche achieved sales growth hemlibra haemophilia polivy blood cancer chf chf billion exceeding companys phesgo breast cancer achieved total guidance year increase made sales chf billion represents plus expected decline covidrelated chf billion compared sales amounting chf billion effects biosimilar erosion cancer medicines vabysmo launched early reached mabtherarituxan herceptin avastin sales chf billion become one totalled chf billion resulting overall bestselling medicines roche impact chf billion diagnostics divisions base business sales swiss franc significantly appreciated versus increased immunodiagnostic products currencies impacting results reported particularly cardiac tests diagnostics swiss francs compared constant exchange rates solutions clinical chemistry advanced staining contributing significantly growth core operating profit chf chf billion good sales performance overall diagnostics division reported return towards precovid sales mix resulted sales chf billion decline improved gross margin offset reflects anticipated significant drop continued investments pharmaceutical research demand covidrelated products sales development launches new products chf billion compared sales additionally patent settlement income chf billion japan affected growth rate lower demand covid testing sales ifrs net income increased chf north america europe middle east chf billion due increase operating africa emea asiapacific regions decreased profit ifrs lower income tax expenses respectively divisions base business grew across regions core earnings per share rose chf including positive impact resolution outlook tax disputes roche expects increase group sales mid single digit range constant exchange sales pharmaceuticals division increased rates core earnings per share targeted chf billion newer medicines develop broadly line sales growth severe diseases continuing strong growth constant exchange rates excluding impact resolution tax disputes top five growth drivers vabysmo severe roche expects increase eye diseases ocrevus multiple sclerosis dividend swiss francs unless otherwise stated growth rates comparisons previous year constant exchange rates cer average rates total figures quoted reported chfroche group roche key figures chf millions group sales pharmaceuticals sales diagnostics sales core operating profit rd core investments chf dividend unless otherwise stated growth rates comparisons previous year constant exchange rates cer average rates total figures quoted reported chf effective january group made certain presentational cost allocation changes income statement comparative information restated accordingly contents letters shareholders sustainability report contribute corporate governance remuneration report diagnostics diagnostics divisions base business sales lower covidrelated sales sarscov increased immunodiagnostic products assays cobas systems particularly cardiac tests diagnostics solutions growth underlying base business included clinical chemistry advanced staining higher sales blood screening well contributing significantly growth diagnostics solutions detection monitoring cervical cancer overall diagnostics division reported virology base business sales chf billion decline reflects anticipated significant drop pathology lab customer area focuses demand covid related products sales pathology labs provides diagnostics solutions chf billion compared sales tissue biopsies companion diagnostics chf billion targeted diagnostics aid choice specific therapies patient lower demand covid testing sales sales increased across regions north america europe middle east due growth advanced staining africa emea asiapacific regions decreased companion diagnostics businesses respectively divisions base business grew across regions point care customer area provides diagnostics solutions immediately point core lab customer area focuses care emergency rooms general central labs provides diagnostics solutions practitioners practices directly patients areas immunoassays clinical chemistry includes sarscov rapid antigen test custom biotech sales increased due blood gas electrolyte bge tests lower growth immunodiagnostic products sales sarscov rapid antigen test cardiac oncology tests main driver sales decrease growth clinical chemistry business growth base business driven sales grew across regions largest liat molecular pointofcare product line contributions sales growth coming asiapacific emea regions grew diabetes care customer area provides respectively diagnostics solutions patients healthcare professionals enabling integrated personalised molecular lab customer area focuses diabetes management sales decreased molecular labs provides diagnostics driven continued contraction blood solutions detection monitoring glucose monitoring market us major pathogens donor screening sexual health european markets due people switching genomics sales declined due continuous glucose monitoring systemsdiagnostics roche sales customer area chf millions core lab molecular lab pathology lab point care diabetes care contents letters shareholders sustainability report contribute corporate governance remuneration report innovation improve patient outcomes maintained momentum strong alzheimers disease common form growth diagnostics base business launching dementia affects million people worldwide range new tests platforms digital solutions number expected triple continued focus innovations supporting however people living symptoms healthcare professionals prevention diagnosis alzheimers yet diagnosed monitoring improve health outcomes received diagnosis waited reducing cost care retained average years symptom onset part position worlds leader vitro diagnostics commitment addressing burden growing portfolio diagnostic alzheimers disease march entered assays instruments around collaboration eli lilly company support world deliver breakthrough innovations development elecsys amyloid plasma greatest possible patient market impact panel eapp eapp innovative blood test aims facilitate earlier diagnosis addition leader laboratory alzheimers disease potentially streamline diagnostics prominent role bringing access future treatment options diagnostics closer patients point ofcare innovations example cancer continues one worlds handheld cobas pulse represents industryfirst greatest health threats across testing disciplines professional blood glucose management solution molecular sequencing immunochemistry features mobile digital health capabilities imaging tissue digital diagnostics offer help improve patient care comprehensive ecosystem solutions ensure laboratories healthcare professionals transforming healthcare delivery meet tools need give patients care global challenges deserve example women die throughout year increased efforts cervical cancer live lmics awarded address critical health challenges including ageing us prequalification cobas hpv test populations increasingly complex medical needs use lmic national cervical cancer elimination around world number patients programmes age growing world health organization estimates one six people diabetes care continued deploying integrated personalised diabetes management billion people sixties older nearly ipdm strategy strengthening market half billion people two common leadership blood glucose monitoring bgm comorbid conditions occurring elderly people thus enabling access care people cardiometabolic diseases dementia diabetes around world connectivity digital solutions play key role vision cardiovascular disease number one cause proudly reached million mortality accounting global registered users diabetes management deaths occur low middle app mysugr making rochediabetes care income countries lmics stronghf study platform healthcare providers available results show ntprobnp biomarker testing countries embedded therapeutic strategy integral part improving care patients heart failurebusiness pedriafogrnmoasnticces rroocchhee roche diagnostics tests delivered customers billion active inlicensing agreements active outlicensing agreements diagnostics analytical units placed cobas pro line facts analytical units placed growth versus cobas pure line growth versus new platforms tests digital solutions pathology lab roche information solutions new tests new digital solutions new digital solution diabetes care diagnostics new digital solutions key launches molecular lab core lab new platform new platforms new tests new tests cobas pro midhigh throughput cobas pure lowmid throughput core lab customers instruments used measurement parameters blood contents letters shareholders sustainability report contribute corporate governance remuneration report innovative insights integrate data across care settings connecting made significant progress strengthening healthcare community accelerating access expanding efforts healthcare digitalisation innovation insights navify approach focus lab insights clinical workflow focuses open digital ecosystems address optimisation clinical decision support patient interoperability enable patientcentric model monitoring segments primarily target labs rather diseasecentred approach support providers patients efficient product development digital solutions committed establishing common navify digital solutions including navify scalable technology stack digital products algorithm suite navify sample tracking securely customers patients key launches activities name launch date approval indicationdisease etc systemplatform tests virsnip sarscov spike january fda research use pcr test detect sarscov xbb variant pcr platforms lightcycler fp ii cobas z idh rh idh glioma february fda neuropathologyimmunohistochemistry ihc solution supporting benchmark instrument series atrx rabbit detection tumour cells idh rh mutation aids polyclonal antibody pathologists diagnosis gliomas identifies mutation status patients diagnosed brain cancer ventana pdl sp march fda label expansion identifies patients nonsmall cell lung cancer nsclc may companion diagnostic eligible treatment libtayo regeneron monotherapy benchmark ultra system cobas hpv test june prequalification enables lmics use cobas hpv test national cervical roche molecular systems cancer elimination programmes eg cobas cobas cobas elecsys il neonatal october countries accepting first il test certified claim use diagnosis cobas e immunoassay sepsis immunoassay ce mark neonatal sepsis immunoassay dedicated claim analysers supporting evidence aiding diagnosis sepsis neonates potential reduce newborn mortality cobas hpv test november fda pcr test identify presence hpv genotypes cobas highrisk hpv types combined result broaden access hpv testing us midsize smaller labs elecsys neurofilament november fda breakthrough test aid detection disease activity adults elecsys technology light chain nfl test device designation years old relapsingremitting multiple sclerosis multiple sclerosis ms rrms secondary progressive multiple sclerosis spms elecsys antihev igm november countries accepting detection hepatitis e virus hev infections treatment fully automated assays run elecsys antihev igg ce mark monitoring prevention disease progression hev testing elecsys technology immunoassays included essential diagnostics list edl elecsys hbeag quant november countries accepting immunoassay able determine presence quantity cobas e analysers ce mark qualitative quantitative hepatitis b e antigen hbeag human serum plasma complements existing hbv testing markersdiagnostics roche key launches activities continued name launch date approval indicationdisease etc systemplatform instrumentsautomation ccm vertical august global cobas connection modules fast transport system connecting cobas p cobas p cobas p cobas p analytics postanalytics cobas pro integrated august china scalable modular swa mid highvolume clinical chemistry cobas systems solutions immunochemistry testing cobas pure integrated october china swa analyser bringing together three diagnostic technologies cobas systems solutions single platform optimise space resources small medium labs lightcycler pro november ce mark fda k new nextgeneration flexible realtime qpcr instrument new lightcycler qpcr instrument exempt status dual ivd research mode plus enhanced system features lumiradx december global roche entered definitive agreement acquire lumiradxs transaction closing expected pointofcare technology combining multiple diagnostic modalities mid single platform digital solutions navify algorithm suite april europe single platform hosting library digital medical algorithms embedded existing healthcare asiapacific generate patientcentric insights initial focus liver disease workflows labhospital colon cancer information system lishis electronic healthmedical record ehremr navify tumor board october attained overall cloudbased digital solution streamlining workflows recognition klas research performance score multidisciplinary collaboration oncology tumour boards first look report hcp navify poc operations october attained overall software connects monitors pointofcare devices recognition klas research formally registered performance score roche nonroche device oversight error first look report countries hcp management test results cobas infinity poc navify lab operations october attained overall lab software consolidates data various instruments recognition klas research formally registered performance score systems automates lab processes optimal lab first look report countries hcp efficiency cobas infinity lab expanded menu november cemarked clinical decision support algorithms areas oncology navify algorithm suite algorithms navify algorithms added cardiovascular metabolics algorithm suite ruo digital pathology december global research digital pathology algorithm scoring pdl sp ventana dp ventana dp algorithm use breast samples slide scanner stained ventana pdl sp assay limited data healthcare professionals best klas software average category contents letters shareholders sustainability report contribute corporate governance remuneration report pharmaceuticals sales pharmaceuticals division increased noninhibitor segment europe chf billion newer medicines international region sales grew across major severe diseases continuing strong growth markets sales japan increased result market penetration united states sales rose vabysmo ocrevus hemlibra main growth drivers perjeta chf billion herpositive increase partly offset declining sales breast cancer sales perjeta grew medicines expired patents international region particularly china brazil key growth driver sales europe grew key contributions partly offset decline sales germany france uk sales growth us result adjustment related us vabysmo phesgo evrysdi hemlibra ocrevus governmental plans excluding adjustment compensated lower sales perjeta sales us showed growth ronapreve medicines expired patents sales perjeta europe lower following launch phesgo japan sales mainly due lower supply ronapreve government tecentriq chf billion cancer excluding ronapreve sales japan grew immunotherapy either alone combinations increase fueled strong performance various types cancer eg lung bladder newer medicines polivy vabysmo breast liver cancer sales increased effectively compensated impact growth across regions us sales biosimilars higher driven nonsmall cell lung cancer nsclc adjuvant indication europe sales international region grew led growth mainly driven small cell china brazil canada china sales rose lung cancer hepatocellular carcinoma tamiflu xofluza cancer medicines polivy indications japan sales increase came tecentriq perjeta key growth drivers growth nsclc adjuvant indication offsetting impact biosimilars international region china key lower sales cellcept growth driver ocrevus chf billion relapsing actemraroactemra chf billion forms multiple sclerosis primary progressive rheumatoid arthritis juvenile idiopathic multiple sclerosis continuously growing arthritis giant cell arteritis car tcellinduced demand indications primarily driven us severe lifethreatening cytokine release growth coming new retained syndrome covid sales increased patients elsewhere ocrevus continued show mainly us despite lower demand high uptake notably germany italy brazil hospitalised patients covid demand outside covid increased hemlibra chf billion haemophilia based continued confidence medicine sales growth continued especially us especially rheumatoid arthritis segmentpharmaceuticals roche topselling pharmaceuticals chf millions ocrevus neurology hemlibra haemophilia perjeta oncology tecentriq oncology actemraroactemra immunology vabysmo ophthalmology xolair immunology kadcyla oncology mabtherarituxan oncologyimmunology herceptin oncology products launched contents letters shareholders sustainability report contribute corporate governance remuneration report innovating patients around world us fda european commission phase iii ocarina ii trial ocrevus twice approved columvi people relapsed ayear tenminute subcutaneous injection refractory diffuse large bcell lymphoma based noninferior intravenous infusion provided results phase iii pivotal data nearcomplete suppression brain lesions columvi given fixed course induced early tenminute subcutaneous injection potential longlasting complete responses heavily improve treatment experience expand pretreated patients columvi given fixed usage people multiple sclerosis ms period time made readily available centres iv capacity limitations providing patients treatment end date treatmentfree period pivotal phase iii imbrave study investigating tecentriq plus avastin people earlystage us fda also approved polivy combination hepatocellular carcinoma high risk recurrence rchp treatment certain types following surgery met primary endpoint previously untreated diffuse large bcell recurrencefree survival lymphoma based polarix trial results phase iii study showed polivy combination tecentriq subcutaneous sc received first reduced risk disease progression relapse marketing authorisation great britain death compared standard care positive opinion european medicines rchop comparable safety profile agencys committee medicinal products combination first fdaapproved therapy human use chmp approval europe nearly years firstline treatment tecentriq sc injected within minutes diffuse large bcell lymphoma free time patients healthcare teams caregivers european commission approved expansion hemlibra european union marketing phase iii alina study alecensa met authorisation label includes routine primary endpoint demonstrating statistically prophylaxis bleeding episodes people significant clinically meaningful improvement haemophilia without factor viii inhibitors diseasefree survival alecensa reduced risk moderate disease fviii disease recurrence death compared severe bleeding phenotype platinumbased chemotherapy people earlystage alkpositive nonsmall cell lung cancer commodore study global phase iii nsclc setting treatment curative programme crovalimab paroxysmal nocturnal intent adjuvant alecensa represents important haemoglobinuria pnh rare lifethreatening blood new treatment strategy patients resected condition met coprimary efficacy endpoints stage ibiiia alkpositive nsclc showing crovalimab achieved disease control people pnh previously data phase iii embark study showed treated complement inhibitors boys aged years duchenne muscular dystrophy dmd treated elevidys showed us fda accepted companys biologics increase north star ambulatory assessment license application bla crovalimab nsaa measure motor function compared treatment pnh placebo weeks primary endpointpharmaceuticals roche major approvals us japan chugai c olumvi p hesgo diffuse large bcell lymphoma herpositive breast cancer thirdline treatment herpositive colorectal cancer p olivy actemraroactemra diffuse large bcell lymphoma cytokine release syndrome major approvals firstline treatment mabtherarituxan v abysmo lupus nephritis retinal vein occlusion central vein mabtherarituxan occlusion branched vein occlusion antibodymediated rejection organ transplantation europe china c olumvi diffuse large bcell lymphoma thirdline treatment c olumvi diffuse large bcell lymphoma thirdline treatment h emlibra moderate haemophilia p hesgo herpositive breast cancer evrysdi spinal muscular atrophy presymptomatic p olivy paediatric months diffuse large bcell lymphoma firstline treatment xofluza p olivy influenza paediatric diffuse large bcell lymphoma relapsed refractory r onapreve evrysdi sarscov hospitalised spinal muscular atrophy presymptomatic paediatric months xofluza influenza paediatric v abysmo neovascular wet agerelated macular degeneration diabetic macular oedema oncologyhaematology inflammationimmunology neurology infectious diseases ophthalmology contents letters shareholders sustainability report contribute corporate governance remuneration report new partnerships personalised healthcare agreements technology discovery licence agreements pilot agreements acquisitions number new partnerships product licence agreements agreements derived product outlicensing existing alliances agreements divestments pharmaceuticals clinical pipeline phase phase ii phase iii registration oncology inflammationimmunology neurology infectious diseases ophthalmology metabolics others pipeline new molecular entities covers broad range diseases highly innovative technologies applied create produce active moleculespphhaarrmmaacceeuuttiiccaallss rroocchhee met clinically meaningful statistically commercialise zna phase tyrosine significant treatment benefits observed kinase inhibitor tki bestinclass potential key prespecified secondary functional endpoints zna specifically designed evaluation data ongoing bloodbrain barrier penetrant address significant unmet medical need associated phase iii inavo study investigating inavolisib brain metastases people metastatic breast combination palbociclib fulvestrant cancer tki potential treat prevent firstline treatment people pikca onset brain metastases patients mutated hormone receptor positive negative endocrineresistant locally advanced building expertise immunology roche metastatic breast cancer met primary endpoint signed agreement acquire telavant demonstrated statistically significant roivant pfizer including rights rvt clinically meaningful improvement progression antibody firstinclass bestindisease free survival pfs inavolisib combination potential treat inflammatory bowel disease reduced risk disease worsening death agreement roche gains right develop doubling pfs compared manufacture commercialise rvt palbociclib fulvestrant alone overall survival us japan data immature time clear positive trend observed followup continue genentech entered strategic collaboration next analysis data inavo study nvidia couples genentechs cuttingedge submitted health authorities artificial intelligence ai capabilities extensive view bringing potential treatment option biological molecular datasets research patients soon possible expertise nvidias worldleading accelerated computing capabilities ai speed drug partnerships complementing portfolio discovery development expanding presence new areas roche entered partnership alnylam end roche entered definitive codevelop cocommercialise phase ii rnai merger agreement acquire carmot therapeutics therapeutic zilebesiran treat hypertension including carmots innovative rd portfolio patients high cardiovascular risk zilebesiran incretinbased clinical preclinical assets bestindisease potential patients portfolio great potential provide new best hypertension high risk cardiovascular morbidity inclass treatments monotherapy well mortality robustly durably lowering various combinations assets treat blood pressure obesity several indications oncology roche signed agreement zion pharma continue developing contents letters shareholders sustainability report contribute corporate governance remuneration report reporting approach roche committed transparent reporting economic social environmental performance report prepared content compliance section six transparency content disclosed based voluntary nonfinancial matters section eight due mandatory disclosure requirements diligence transparency relation minerals company strategy metals conflictaffected areas child labour swiss code obligations content covers nonfinancial matters respective implementing ordinance due accordance section six transparency diligence transparency relation minerals nonfinancial matters gri universal metals conflictaffected areas standards child labour content covers riskbased due diligence alignment latest global reporting operations supply chain upstreams initiative gri universal standards issued identify prevent mitigate account actual potential adverse impacts reporting scope boundaries reasonable grounds suspect products report covers regions divisions services manufactured provided using roche group january december child labour accordance section eight scope defined outlined due diligence transparency relation document nonfinancial reporting indicators minerals metals conflictaffected definitions scope areas child labour swiss code gorochecomnonfinancialreportingscope annual report arrochecom rochecomarepdf rochecomfbepdf risk management rochecomriskmanagement key performance indicators rochecomperformanceour reporting approach roche obligations well provisions forwardlooking statements forward ordinance due diligence transparency looking statement speaks date relation minerals metals conflict statement roche undertake affected areas child labour obligation publicly update forwardlooking financial data mentioned business statement whether result new information performance section summarised future events otherwise aggregated information financial information provided may based statements prepared accordance internally developed methodology international financial reporting standards figures rounded ifrs issued international accounting percentages calculated using rounded standards board iasb numbers nonmaterial data information provided based reasonably excluded diligent data collection process second line controls order reflect accurate information external assurance material aspects within reasonable selected key figures nonfinancial opinion roche taking particular account reporting year ended december size complexity roche group subject limited assurance procedures operations inadvertent errors information performed thirdparty assurance provider may occur inaccuracies may particular pricewaterhousecoopers ag pwc particular difficult observe reasonable level areas safety security health materiality environmental protection ii people culture forwardlooking statements guarantees iii grants donations sponsorships future performance developments actual results developments may differ see independent practitioners limited assurance materially expectations expressed report contents letters shareholders sustainability report contribute corporate governance remuneration report key sustainability topics initiated refreshed materiality assessment process initial results materiality process based double materiality principles analysis shared roche corporate identify sustainability topics executive committee shared significant impact people environment endorsement progress roches longterm business success ongoing assessment builds previous purpose report key materiality assessments sustainability topics following prioritised first phase assessment focused stakeholder engagement exercise collected environment quantitative data internal external climate change ghg energy stakeholders priority sustainability topics air pollution internal stakeholders comprised randomly water selected group roche employees external stakeholders consisted various groups including social patients caregivers healthcare practitioners product innovation research governments policymakers based patient health wellbeing quantitative inputs bestpractice sustainability access affordability frameworks created topic map c ommunities employee rights workforce dei following mapping exercise additional h uman rights responsible resilient quantitative qualitative data collected value chains internal external stakeholders internal stakeholders subjectmatter governance experts within organisation external corporate governance stakeholders comprised various groups including compliance business ethics academia industry bodies associations risk management investors patient organisations suppliers data governance privacy cybersecurity derived key sustainability topics transparency accountability reporting sustainability rochecomsustainability materiality rochecommateriality stakeholder engagement rochecomstakeholderengagement key performance indicators rochecomperformance contribution un sdgs rochecomunsdgsour key sustainability topics roche key sustainability topics environment social governance minimise impact contribute better embed transparency planet tomorrow compliance everything climate change ghg energy product innovation research corporate governance air pollution patient health wellbeing compliance business ethics water health equity risk management biodiversity access affordability data governance privacy cybersecurity c ircularity responsible marketing labelling ransparency accountability sustainable health systems reporting communities stakeholder engagement employee rights workforce dei human rights responsible resilient value chains industry bodies associations academics thought leaders governments policymakers assurance firms regulators expert service providers payers providers patient organisations overview subjectmatter expert segments consulted ngos mlos suppliers peers internal smes labs investors subjectmatter experts nongovernmental organisations multilateral organisations contents letters shareholders sustainability report contribute corporate governance remuneration report partnering patients connecting work patient needs requires us move beyond patient centricity patient inclusivity pharmaceutical industry inherently science evaluating potential benefits risks based rooted belief good science scientific discoveries patient populations results good products advancing science relevant representative realworld core focus roche also believe setting approach patient insight integration scientific innovations valuable serve also involves early assessment impact patients way want need innovations health systems prioritise investments advance past year focused applying beneficial molecules diagnostics belief development efforts integrating development patient insights patient experience data patient preference process effort ultimately goal create internal weve strived balance scientific discoveries ecosystem patients heart understanding patients including work included integrated historically underserved underrepresented processes partners challenge patients need desire care shape science enabling roche define redefine standard care diseases work driven global patient network actively focus team guided proprietary patient benefits societal impact framework captures making patient inclusivity core priority every prioritised actionable insights employee every function every country gaps patients experience care way ensure patient voice current future patient needs embedded decisionmaking patient feedback new medicines diagnostics roche also within healthcare systems integrated healthcare solutions designed address pressing development patient needs benefits patients seek treatments overall care maintaining high standards patient stakeholders embedding patient voice end end work however must done integrity strive embed patient voice end transparency ensure unduly end disease area strategies influence patient communities relation work begins empowering early research innovations reason roche consistently teams focus discovery partnering applies high standards conduct development programmes patient needs collaboration patient stakeholderspartnering patients roche key sustainability topics patient health wellbeing responsible marketing labelling stakeholder engagement advancing science core focus roche also believe scientific innovations valuable serve patients way want need contents letters shareholders sustainability report contribute corporate governance remuneration report roche group code conduct roches offered organisations like patient focused position partnering patient communities medicines development pfmd european roche directive collaborating patients academy therapeutic innovation patient groups patients establish guiding eupati principles govern actions employees core documents commitment principles outline commitment mutual value mutual reflected annual disclosure funding respect integrity equity independence nonmonetary support provided patient transparency also form basis organisations around world disclosure robust training programmes provided core component sustainability overview employees may interact patients reflection approach maintaining based include elements training productive purposeful relationships patient view global rankings made available ranking big pharma pags ranking companies pags worked us worked us overall portfolio st rd patient organisations nd rd cancer overall st st patient organisations nd nd breast cancer st st patient organisations nd nd blood cancer st st patient organisations th th lung cancer st st patient organisations nd nd ophthalmology st companies evaluated ophthalmology patient organisations nd big pharma rare diseases st st patient organisations st st rare bleeding disorders st st patient organisations st st neurology st st patient organisations st st multiple sclerosis st st patient organisations st nd neuromuscular disorders nd companies evaluated neuromuscular patient organisations st disorders big pharma patient advocacy groups rochecomaboutgovernancecodeofconduct gorochecompositiononpartneringwithpatientcommunities gorochecomcollaboratingwithpatientgroupsandpatientspartnering patients roche patientfocused roles help roche integrate voice feedback patients development commercialisation efforts patient partnership teams patient experience teams serve primary relationship managers build maintain drive roches collaborations help design implement programmes patient organisations well individual patients solutions improve experience carers patient partnership leads also patients roche group known patient advocacy leads country individuals focus understanding level proactively drive roches collaborations patients navigate healthcare systems patient community bring feedback offer beyond pill services relevant insights teams may digital health solutions endtoend patientfocused develop medicines diagnostics integrated health patient support programmes enhance solutions high value patients teams roles experience outcomes work across full lifecycle roches innovations shape clinical development well access strategies ensure every patient benefit companys innovations access patient journey partners pjps healthcare system partners hsps local roche representatives work closely serve local face roche key healthcare patients well stakeholders system stakeholders policymakers organisations directly impact patient regulators payers patient organisations journey country level pjps deep improve patient access healthcare hsps identify knowledge local health system shared purpose value partners drive identify unmet patient needs roche health system innovation cocreate solutions may develop solutions add value improve deliver value patients local patient outcomes health ecosystem patient organisations engage roche across world chf million provided grants sponsorships donations worldwide patient community contents letters shareholders sustainability report contribute corporate governance remuneration report access healthcare roche supports expansion universal health coverage key component united nations sustainable development goals sdgs access healthcare core element roches full range quality health services whenever sustainable business strategy work identify wherever need without financial address root causes preventing access hardship innovative healthcare global country local levels also work closely partners yet find halfway towards develop deliver tailored access solutions deadline achieving sdgs world reflect countrys unique healthcare needs significantly track meet target stated sdg progress report commitment sustainable healthcare wake pandemic progress towards reflected roche group code conduct uhc slowed financial hardship employees expected ensure access risen also reported around programmes compliant applicable laws million people global population regulations industry codes collaborate pushed pushed extreme transparent responsible way different poverty due outofpocket payments cover stakeholders enable access products health costs services policies provide guidance ethical collaboration different stakeholder key elements achieving uhc groups including patients patient organisations global healthcare company working healthcare professionals healthcare organisations innovative therapeutics diagnostics government officials member uhc private sector constituency made clear commitment importance uhc sdgs support adoption uhc believe world leaders agreed united nations public funding complemented sustainable sdgs shared blueprint peace prosperity funding financing mechanisms people planet one goals public private sectors fundamental sdg aims ensure healthy lives promote achieve uhc wellbeing ages healthcare company know important role uhc must include noncommunicable diseases play sdg including supporting access ncds cardiovascular diseases cancers innovations chronic respiratory diseases diabetes ncds kill approximately million people year one way facilitate access innovations equivalent deaths globally supporting expansion universal health coverage uhc key component sdgs also vital screening early diagnosis uhc means people access treatment built integrated gorochecomungoals rochecomaboutgovernancecodeofconductaccess healthcare roche key sustainability topics patient health wellbeing health equity access affordability responsible marketing labelling sustainable health systems communities stakeholder engagement support empower programme kenya one various initiatives around world provide sustainable patient access quality affordable healthcare ultimately support expansion uhc contents letters shareholders sustainability report contribute corporate governance remuneration report healthcare system supported backbone kenya women screened labstrengthening connected laboratory breast cancer cervical cancer networks adoption programme also seen men resolution strengthening diagnostics capacity screened prostate cancer see growing political recognition value diagnostics deliver improved care peru collaboration peruvian ministry encouraging member states adopt national health government organisations patient diagnostics strategies way ensure effective advocates groups peru roche allocation limited resources supporting implementation national cervical cancer screening programme goal working partnership towards uhc ensure women access improved care roche long supported uhc work cities remote villages along amazon global regional local levels collaborating highest cervical cancer multiple stakeholders address care rates found programme gap ranges working screening serves sites peru nearly women programmes healthcare workforce capacity tested hpv infection past building beyond working initiatives two years choosing sample around world provide sustainable patient selfcollection roche trained around access quality affordable healthcare healthcare providers programme ultimately support expansion uhc worked ministry health improve indonesia roche working closely care highrisk hpvpositive patients government local partners two unique projects first aims strengthen pakistan supporting screenher oncology nursing capacity increasing plan project improve diabetes management number trained nurses deliver basic women developed partnership specialised oncology nursing care greenstar social marketing guarantee limited second project introducing establishing project allows women underprivileged areas cancer patient navigator professionals help access diabetes risk assessment education patients families navigate complex testing would otherwise difficult treatment journey get also allows earlier diabetes diagnosis management improving overall health outcomes kenya supporting empower hope reach one million women programme establish clinics provide next three years integrated care breast cervical cancer ncds programme partnership world seeks catch uhc public private nonprofit implementation ahead roche remains organisations aims overcome systemic committed working partnership private healthcare challenges lack screening public stakeholders around world address access medicines since launch overcome local challenges building strong clinics established across resilient healthcare systems allaccess healthcare roche laboratory professionals patients africa trained global access program scope low lowermiddleincome country llmic address critical shortages lab technicians support access goal used core medicines aim need quality diagnostic services double access patients million women roches core medicines tested roches hpv highrisk testing approved approval progress women llmics compared low middleincome countries access billion roche diagnostics tests around patients llmics delivered customers worldwide world treated roche medicines compared llmics cities children continue work city cancer challenge active cities worldwide reaching countries reached estimated million people changing diabetes children programme partnership novo nordisk since launch screenher programme pakistan launched partnership greenstar social marketing guarantee limited improve diabetes management women goal reach one million individuals next three years saw decline use actemraroactemra covid however compensated increases medicines contents letters shareholders sustainability report contribute corporate governance remuneration report diversity equity inclusion diversity equity inclusion dei key components roches sustainabilityfocused identity see dei critical lever enables prevent people accessing quality care innovation medicines diagnostics partnerships driving inclusive research solutions helping millions patients expanded include sites across us uk contributing healthier communities canada south africa kenya morocco nigeria employer committed fostering india work environment employees thrive one example roches partnership omnigen analyse health genetic information newly created global chief diversity officer patients south africa project aims role visible important milestone address relative lack genomic data efforts towards holistic global approach people african descent better health data allows caroline creven fourrier appointed roche develop effective drugs targeted role leading team set standalone therapies novel biomarkers expand market group closely connected business access improve patient outcomes globally read executives role involves taking responsibility work close representation gaps roches dei strategy strengthening internal dei community driving internal external efforts accelerate realisation building workforce reflects societies roches dei vision ambitions serve rely creativity diverse ideas focus equity people create innovative healthcare solutions recently updated dei strategy add improve outcomes patients equity critical focus area equity always made progress improving data quality inherently included efforts transparency helping employees grow wanted call explicitly roche understanding importance dei equity means giving people groups fair access around globe improving data quality opportunities consideration unique sharing data transparently across differences create equal outcomes organisation encourage greater accountability collective action towards dei strategy addressing unmet needs diverse patients goals addition communicated dei communities narrative employees better understand committed contributing science connection dei strategy advancing inclusive research diverse patient ability innovate behalf patients around populations globally reducing barriers globediversity equity inclusion roche key sustainability topics employee rights workforce dei rely creativity diverse ideas people create innovative healthcare solutions improve outcomes patients contents letters shareholders sustainability report contribute corporate governance remuneration report roche two corporate goals focused gender inclusive culture strengthened nationality catalyse action across collective efforts diversity networks organisation aim achieve improvement fortyfive new diversity networks formed year year measures serve proxies bringing total see numerous often immeasurable dimensions diversity people bring roche globally advancing positive change society set target increase proportion diverse partnerships women executive positions dei strategy encourages development represented nationalities executive positions local partnerships diverse stakeholders focused building create positive ripple effect communities inclusive talent pipelines increasing equity across globe roche strengthened underrepresented talent aim drive partnerships add value patients society progress corporate diversity goals healthcare roche fostering greater see chart appreciation dei globally locally one example mission leapfrog initiative aims embedding dei practices ensure transform patient wellbeing population everyone best health asia partnering people across work thrive region cocreate breakthroughs continued embed dei practices project hopes trigger transformative leapfrog across operations foster greater inclusion progress improves health outcomes roche global dei learning portfolio underserved populations accessible employees portfolio available global learning proactively addressing demographic shifts platform includes trainings bias awareness workplace expectations policy changes intercultural awareness psychological safety dei landscape constantly evolving help employees expand understanding requires continued focus investment build skills support dei strategy global demographic shifts population ongoing awareness campaign dei starts growth low middleincome countries helps raise awareness important along generational shift workforce issues creates lasting positive change expect current future organisational across roche driving doable incremental needs mirror dynamics roche also actionable changes across employees proactively taking steps meet changing campaign reached people regulatory requirements call additional previous campaigns focus dei particular attention health equity disability ethnicity age inclusion index global employee opinion survey geos measured supporting global dei commitments perception inclusion roche focusing roche committed creating diverse equitable inclusion authenticity respect inclusive workplace human rights score remaining stable respected safe working conditions ensureddiversity equity inclusion roche global dei corporate goals set target achieving share women executive positions underrepresented nationalities executive positions per q baseline additionally invite leaders across roche make additional commitment relevant local culture context women underrepresented nationalities q q q q q q q q q q q q goal diversity networks chapters around globe agegeneration raceethnicity disability gender lgbtq dei veterans intersectional diversity networks grassroots selforganised groups employees coming together contribute dei mission organisation specifically aimed embracing unique power person transform lives patients society includes individuals countries asia latin america eastern europe middle east africa e xcludes chugai workday lite companies companies use roche workday system leading hr system due armslength alliance mergeracquisition agreements illustrative map diversity networks chapters exhaustive ccoonntteennttss lleetttteerrss ttoo sshhaarreehhoollddeerrss ssuussttaaiinnaabbiilliittyy r reeppoorrtt hhooww w wee c coonnttrribibuuttee ccoorrppoorraattee g goovveerrnnaannccee rreemmuunneerraattioionn r reeppoorrtt employees region north america asia parttime africa australianew zealand fulltime latin america europe pharmaceuticals chugai diagnostics corporate employees divisionodg female age distribution gender male number employees expressed fulltime equivalents december operating divisional groupddiivveerrssiittyy eeqquuiittyy aanndd iinncclluussiioonn rroocchhee united nations global compact ungc organization ilo specifically conventions signatory commit integrate universal iloioe child labour principles areas human rights labour guidance tool business environment anticorruption business ten principles united nations global strategy culture daily operations compact united nations guiding principles business valuable commitment supports disability human rights ungps inclusion signatory un universal declaration human rights udhr standards conduct business tackling discrimination lgbtq people also mechanisms mitigate risk related dei recently signed zero health gaps pledge take holistic approach ensuring employees world economic forum wef pledge compensated fairly diversely represented aligns commitment address barriers provided equitable opportunities work safe clinical trial participation diversify genetic data fulfilling environment free discrimination scientific discovery increase access addition described ethical innovative diagnostic therapeutic solutions business practices human rights safety advancing inclusive research read health wellbeing chapters two work area additional key mechanisms use continuously track communicate progress approach dei outlined employees corporate goals refine roche group code conduct approach achieving including quarterly roche group employment policy communicate reviews corporate executive committee expectations suppliers roche regular engagement people directive human rights due diligence culture teams directly involved business partners conduct organisationwide pay equity analysis every three years also roche acknowledges committed conducted livingwage analysis repeat internationally respected standards guidelines periodically future including fundamental principles rights work stipulated international labour gorochecomrochethevaluable gorochecomunfestandards gorochecomzerohealthgapspledge gorochecomadvancinginclusiveresearch rochecomaboutgovernancecodeofconduct gorochecomrochegroupemploymentpolicy gorochecomhumanrightsduediligenceforbusiness contents letters shareholders sustainability report contribute corporate governance remuneration report safety health wellbeing roche strives innovative company employees proud part partners trust committed maintaining safety promotion promote mental health security health environmental principles wellbeing part roches global wellbeing practices outlined roche group code initiative livewellroche conduct principles establish uniform minimum standard across roche support every employee access local companies workplaces employees expect employee assistance counselling programme suppliers service providers uphold including counselling psychological stress standards operations work well home life also offer network dedicated mental health champions mental health top mind mental health first aiders help reduce roche take mental health seriously stigma surrounding mental health conditions strive create culture everyone create safe space employees thrive feeling supported psychologically safe responsibility workplace mental health since reported maturity shared global local levels health risk assessments management supported senior management leader particular psychosocial risks set responsibility prioritise mental health ambitious goals see illustration wellbeing people helping people roche rated one top thrive nonnegotiable part people leaders improvers ccla corporate mental job fostering open dialogue create health benchmark ranks companies based culture everyone flourish says thomas strength management commitments schinecker roche ceo continued public reporting mental health ranked establishing effective efficient holistic tier benchmark global mental health wellbeing programme programme centred three pillars wellbeing company actively shaping present protection assessment psychosocial future healthcare passionate risk factors work part comprehensive fostering health wellbeing culture work workplace risk assessment mandated roches holistic approach wellbeing takes roche workplaces organisational individual perspectives rochecomaboutgovernancecodeofconductsafety health wellbeing roche key sustainability topics employee rights workforce dei actively shaping present future healthcare roche considers safety wellbeing employees top priority contents letters shareholders sustainability report contribute corporate governance remuneration report account global live well hub offers total body wellbeing wellbeing resources individuals teams country operate create topics including psychological safety mental health support safe inspirational spaces mindfulness gratitude employees fun challenge share passion offer range wellness measure report employee wellbeing resources tailored employees needs primarily global employee opinion stage life including meditation mindfulness survey geos see table resources sleep tools resilience training coaching counselling sessions well fitness livewellroche options many initiatives driven year sites hold two live well weeks employees promote healthy lifestyles physical mental emotional wellbeing offered safety workplace global events thousands employees forms work roche must safe whether attending celebrated genuine connections tasks urgent complex routine aim fostered sense community ignited minimise number occupational accidents sense purpose placed particular emphasis per year number accidents causing topic womens health especially menopause absence work lost time accident frequency offering keynotes awareness sessions guidelines rate per worked hours approach safety workplace recognised addition global live well community dow jones sustainability indices supports employees care roche rated th percentile others much care patients occupational health safety compared dedicated live well champions across industry benchmark roche network help boost awareness impact employee health wellbeing global employee opinion survey geos indices environment culture health wellbeing na impact overall health na na applicable measures gathered according independent third party provides services geos survey roche aims continuously improve used survey measures currently measured following three items roche takes genuine interest employees wellbeing able successfully balance work personal life roche offers healthy workplace currently measured following two items current state wellbeing allows perform job effectively able cope effectively workrelated stress currently measured following item impact work roche overall health positivesafety health wellbeing roche employee psychosocial risk assessment management goal reached commitment approach culture scores fiveyear goal maximum score employee health safety total number lost time accidents lost time accident frequency rate contents letters shareholders sustainability report contribute corporate governance remuneration report ethical business practices human rights roche convinced integrity essential success sustainability business roche group code conduct clearly expresses well solutions tools enable roches expectations employer relating implementation business strategy ethical business practices human rights provides employees practical guidance good example launch roche examples references useful group directive employees engaging external information commitments clarifies expectations regard handling potential conflicts interest ensure high ethical standards upheld establishes digital tool making process roche relies robust comprehensive consistent transparent simple compliance management programme employees programme covers relevant areas including proper compliance training communication risk efforts radically simplify directive opportunity management anticorruption policy due personal use social media aim ensure diligence dealing business partners effective compliant use social media suppliers mechanisms identifying reporting employees another example multidisciplinary investigating compliance concerns including task force updated directive refreshing protection whistleblowers retaliation content modernising look feel make clearer accessible employees embedding strong ethics culture everything remains main focus compliance example solutionoriented collaboration programme know success area enabling implementation business strategy depends comprehensive accessible successful rollout business partner compliance programme employees management checklist provides guidance compliance ambitions reflect aspiration proper management external business partners see table mind actions allows affiliates test maturity level focused effective education culture regard process including important elements integrity simplification directives processes due diligence human rights compliance ambitions strong culture integrity drive compliance leadership ethical mindset via continuous education line managers promoting ownership roche leaders role models compliance behaviour agile environment compliance programme simple regularly revise modernise existing processes policies supports quick decisions develop compliance digital solutions spirit oneroche develop oneroche data digital strategy healthcare compliance enable implementation effectively collaborate across functions accelerate learning business strategy base decisions focus areas outcome comprehensive risk opportunity management process solutionoriented collaboration continuously develop compliance community serve business needsethical business practices human rights roche key sustainability topics human rights responsible resilient value chains compliance business ethics risk management convinced integrity essential success sustainability business ensure high ethical standards upheld rely robust comprehensive compliance management programme contents letters shareholders sustainability report contribute corporate governance remuneration report compliance business conduct culture roche convinced integrity essential ensuring success sustainability business roche group code conduct developed alignment roche values integrity courage passion code contains guidance areas products services personal integrity corporate integrity employment company assets responsible business comprehensive compliance management also provides questions answers examples information find detailed guidance various topics employees others acting behalf roche must comply roche group code conduct regardless location nature work following oneroche approach principle standards equally binding group functions pharmaceuticals diagnostics division rochecomaboutgovernancecodeofconduct policies targets behaviour business directive defines expectations business conduct defines business integrity actual business conduct perception ethical behaviour business line roche group code conduct commitment run business socially responsible way gorochecombehaviourinbusiness prevention roche rejects forms corrupt business behaviour bribery improper advantages theft fraud embezzlement misuse company detection corruption assets key expectations regarding integrity set forth roche group code conduct behaviour business directive bribery specifies provides explanations specific aspects anticorruption antibribery gorochecombehaviourinbusiness anticorruption roche employees well businesscritical business partners trained key compliance principles global mandatory antibribery training elearning elearning focuses following topics bribery improper advantages gifts entertainment conflict interest discrimination harassment responsible use social media electronic communication tools business partners supply chain employees required complete elearning join roche well periodic refreshers roche group code conduct gets updated rochecomaboutgovernancecodeofconduct anticompetitive maintenance high ethical standards adhering national international laws one fundamental roche corporate principles behaviour prevention policy company comply strictly respects competition laws roche supports efforts promote detection protect competition behaviour competition directive designed make management employees aware basic rules rules affect business behaviour making commercial decisions gorochecombehaviourinbusinessethical business practices human rights roche compliance continued handling non compliance anyone becomes aware potential violation roche group code conduct bring attention events including compliance experts corruption bribery andor anticompetitive events roche employees contractors use following reporting channels chief compliance officer compliance officers network worldwide roche group code conduct help advice line case compliance questions uncertainties roche group speakup line report good faith suspected violation roche expects employees speak believe good faith someone done may something violates roche group code conduct roche group speakup line comprises web telephone service enables reporting compliance concerns confidentially anonymously also available everyone roche employee contractor roche group speakup line operates countries languages making available worldwide employee raises compliance concern good faith acts interest roche deserves acknowledgement roche tolerate retaliation employee raises compliance concern good faith roche takes noncompliance reports seriously fully committed efficiently timely investigate assess facts necessary take adequate corrective measures sanctions business ethics incident management system beims enables management chief compliance officer chief audit risk advisory executive capture track monitor alleged violations initial reports resolution rochecomaboutgovernancecodeofconduct roche group code conduct violations employees externals used roche result employment contracts contracts group speakup line operated external business partners terminated provider qualified alleged violations code conduct increase numbers reported alleged violations compared last year due opening chief compliance officer received total speakup line external people ii still due channels reports alleged violations broadening scope definition business code conduct via business ethics incident ethics incident removal materiality management system unfounded criterion march founded still investigation annual report reference roche group code conduct violations rochecomarepdf contents letters shareholders sustainability report contribute corporate governance remuneration report human rights commitments human rights report child labour roche fosters human rights globally compliance section eight due diligence operations across value chain transparency relation minerals metals evolving holistic approach value chain conflictaffected areas child labour towards proactive approach improving human swiss code obligations well provisions rights committing harm making implementing ordinance due diligence impactful positive contribution society transparency relation minerals metals conflictaffected areas child labour roche supporting implementing roche scope due diligence united nations un guiding principles reporting obligations minerals metals business human rights became conflictaffected highrisk areas article signatory un global compact said ordinance equally committed supporting ten un global compact principles universal declaration risk management human rights international labour risk management approach designed organization ilo declaration fundamental systematically identify assess mitigate principles rights work conventions adequately manage risk human rights commitments violations including assessment whether embodied roche group code conduct reasonable grounds suspect roche group employment policy child labour updated roche position respecting human rights supplier code conduct conducted group human rights risk roche directive human rights due assessment operations thirdparty diligence business partners operations purpose identify assess potential negative human rights impacts section report covers obligations activities business relationships focus due diligence transparency relation operations upstream supply chain rochecomaboutgovernancecodeofconduct gorochecomgroupemploymentpolicy gorochecomrespectinghumanrights gorochecomsuppliercodeofconduct gorochecomhumanrightsduediligenceforbusinessethical business practices human rights roche group human rights risk assessment threeyear cycle review update assess communicate identify human rights risks roche may establish form frequency potentially cause contribute communication accessible activities directly linked intended audiences operations products services educate internal external business relationships stakeholders consolidate prioritise impactbased risks annual cycle define risk mitigation strategiesplans track integrate monitor risk mitigation strategiesplans collect feedback internal external coordinate relevant internal functions risk affected stakeholders leverage materiality responsibility risk owners budget allocations assessment process possible processes put mitigation strategiesplans action establish appropriate qualitative quantitative indicators contents letters shareholders sustainability report contribute corporate governance remuneration report following focus areas based impact identified operations focus areas background commitments prevention mitigation data privacy data valuable element developing innovative treatments roche collects data compliance applicable data privacy laws eg swiss diagnostic solutions patients driver business excellence federal act data protection eu general data protection regulation strive respected preferred partner may us health insurance portability accountability act expected provide data like employees patients healthcare service providers collaboration partners stakeholders comprehensive risk assessment mitigation process ensures privacy roche committed collecting using data lawful fair design default privacy principles always considered legitimate ethical way always respect privacy individuals order earn deserve trust roche applies appropriate governance safeguards measures protect individuals privacy rights group privacy officer together global privacy office coordinates global network subjectmatter experts privacy coordinators roche affiliates global regional business functions close collaboration global security privacy governance global functions access access healthcare part sdg ensure healthy lives trusted partnerships global regional local stakeholders healthcare help governments address relevant access gaps build strong resilient healthcare company roche plays role collaborating healthcare systems including llmics according world bank different stakeholders improving prevention treatment worlds population live management noncommunicable diseases infectious diseases hiv tuberculosis hepatitis c every country different situation healthcare systems present unique challenges work closely partners develop deliver also accelerating ongoing efforts goal double tailored access solutions reflect countrys individual healthcare needs number patients treated innovative therapies low lowermiddleincome countries llmics end global access program created enable access reliable diagnostics also ambition double patient access novel patients llmics leveraging worldclass expertise innovation core highmedicalvalue diagnostics people around world component help control eliminate diseases hivaids tuberculosis hepatitis c covid human papillomavirus hpv cervical cancer fair safe work roche committed fair working conditions respecting roche aims prevent noncompliant behaviour fostering culture openness environment human rights commitments reflected roche group questions provide designated contacts address uncertainties code conduct roche group employment policy roche roche group code conduct condemns forms child forced compulsory labour roche tolerates employment juveniles lawful roche companies ensure roche group employment policy conditions adequately safeguard wellbeing properly implemented local employment practices local policies developed communicated meet minimum standards roche tolerate form psychological physical sexual harassment roche observes regulations area respect employees violation dignity respect employees anyone else potentially affected activities workplace risk assessments workplace mitigation plans performed every affiliate form workplace discrimination based gender age ethnicity national origin religion disability sexual orientation management system approach place identify control safety security hivaids status citizenship generic information health environmental risks exposure workers occupational health relevant characteristics protected applicable law hazards prevented adequately controlled risks measures taken control documented workplace health risk assessments workers roche prevention key element activities decisions offered health surveillance exams provided information training measures aimed ensuring safety security health environmental protection holistic approach wellbeing taking organisational aspects individual perspective accountethical business practices human rights roche following focus areas based impact identified supply chain focus areas background commitments prevention mitigation working conditions suppliers committed pay workers according applicable wage require suppliers explicitly acknowledge adhere laws including minimum wages overtime hours mandated benefits principles embodied supplier code conduct suppliers must ensure consider remuneration accordance skills performance suppliers appropriately ensure compliance experience workers based local competitive conditions principles along supply chains healthy working suppliers expected committed protecting human health environment understanding relevant workplace hazards effectively suppliers shall also ensure roche verify compliance communicating hazards related protection potentially supplier code conduct pscibased supplier sustainability impacted workers assurance visit ssav programme fair treatment suppliers expected committed providing workplace free nondiscrimination harsh inhumane treatment workplace free harassment business partners identified higher risk human rights violations discrimination given type business relationship roche included list business partner auditable entities scheduled suppliers focus area particularly relevant migrant pscibased audits workers reasons national origin suppliers fail meet roches expectations topics outlined roche supplier code conduct might disqualified working roche current suppliers expectations met mitigation plan put place event noncompliance may lead termination pharmaceutical supply chain initiative psci gorochecompscinitiative respecting human rights supply chain expectations covered supplier roche holds suppliers high performance code conduct suppliers expectations concerning human rights contractually obligated adhere aligned values principles shared updated version supplier code conduct suppliers containing human rights commitment business human rights aspects freely chosen labour partners based pharmaceutical supply child labour young workers fair treatment chain initiative psci principles nondiscrimination wages benefits working committed principles referenced hours forced compulsory labour responsible roche contracts embedded provisions sourcing minerals metals roche supplier code conduct suppliers commit ensure protection human rights throughout roche value chain human rights focus following human rights aspects aspects integral part riskbased due freely chosen employment diligence process upstream supply chain child labour potential existing suppliers legal treatment young workers business partners formal process fair treatment nondiscrimination methodology identify prevent mitigate working conditions wages benefits working account actual potential adverse impacts hours human rights enhance transparency within freedom association right collective sphere influence also expect suppliers bargaining business partners actively assess manage health safety human rights risks business partners contents letters shareholders sustainability report contribute corporate governance remuneration report roche directive human rights due diligence precontract business partners sets forth framework roche risk management programme principles ensure protection human rights designed systematically identify assess across roche value chain global guidance mitigate adequately manage risk due diligence process including instruction human rights violations ensure develop implement appropriate due business partners meet roches expectations diligence local markets provided throughout procurement life cycle roches due diligence process protecting human assessment human rights risk embedded rights business partners includes standardised due diligence process identification risks impact assessment conducted engaging new business considering actual potential risks partners roche procurement professionals human rights violations operations considering offering opportunities business business partners activities related partners use online tool developed roche business adequately weighted prioritised create risk profile business partner according severity likelihood roche includes initial assessment business provides mechanisms raise concerns partners risk human rights violations roche employees business partners methodology used mirrors methodology initiating implementing corrective described next section remedial measures needed systematic regular review risk supplier engaged without identification impact assessment assessed accordingly regards potential identification active management risk human rights adverse impacts continuous process undertaken active engagement stakeholders potentially impacted supportive documentation evidencing adequate due diligence process stored line roches corporate records management programme requirements applicable laws reporting relevant legally binding human rightsrelated activities related key performance indicators kpis maintained ensure proper recordkeeping transparency stakeholders gorochecomhumanrightsduediligenceforbusinessethical business practices human rights roche ongoing human rights risk management identification business partners subject human rights audits supplier sustainability assurance visit ssav programme formal annual process methodology assessing business partners mentioned depending circumstances riskbased due diligence order identify higher risk human rights violations business partners actions may undertaken ensure issues human rights violations high risk subject formal audits programme established assess detected addressed per riskbased approach principles oecd due business partners compliance roche supplier code conduct diligence guidance responsible business may conduct onsite criteria used include following audits highrisk suppliers directly evaluate supplier human rights associated industry likely employ vulnerable populations compliance overall supplier performance requirements roche located region higher risk human rights violations per respected supplier code conduct via pscibased ssav programme key characteristics human rights indices ssav include following associated government media internal reports alleged behaviour regularly updated list auditable suppliers identified inclusion list operations indicate real potential noncompliance roche supplier riskbased method previously described code conduct annual audit plan communicated relevant internal stakeholders eg supplier relationship managers global procurement leadership risk managers inputs automated human rights risk assessment methodology allows use psciapproved independent auditors traceability supply chain include external perspective risk documented audit reports using psci templates following psci standard assessment depending four main externally available recognised indexes classifying findings based level risk kidsrights index global slavery index oecd index global rights index using documented action plans submitted audited suppliers monitored following data timely closure nature product service procurement category code identifying followup audits ensure adequacy action plans continuous suppliers exact industry nature product service assess improvement associated human rights risk looking activities typically associated disclosure programme kpis various roche public reporting mechanisms vulnerable populations children underage workers migrants including roches external website local underprivileged communities people low levels education documented ssav programme manual describing aspects programme exact location business partners operations assess area region associated higher levels human rights violations ie limited ssav programme also embeds subtier oversight per psci protocols based regulation enforcement transparency obligations suppliers commit according roche supplier history new information potential risk data input external reports code conduct therefore ssav audits include following concerns raised particular business partner region industry review supplier programmes management systems place ensure human rights suppliers suppliers adequately protected business partners identified higher risk human rights violations direct assessment human rights labour compliance associated included list business partner auditable entities scheduled subtier suppliers working supplier sites time audit pscibased audits part ssav programme suppliers found compliance principles serious concerns related suppliers ability meet roche performance expectations exist roche demands immediate corrective action immediate corrective action possible concept correct issues including concrete time schedule last resort severe issues supplier able willing correct roche terminate business relationships supplier disqualify future opportunities contents letters shareholders sustainability report contribute corporate governance remuneration report grievance mechanism allegations taken seriously employees well business partners objectively investigated full protection encouraged speak good faith believe retaliation practice person spoke human rights violation occurred identified anonymous provided also covers reasonable concerns allegation substantiated take appropriate existence potential actual adverse impact remedial measures related child labour reporting roche group speakup line available substantiated incidents related everyone internally externally report human rights violations triggered terminations compliance concerns contracts incidents related discrimination harassment involving roche local regional compliance officers also employees contractor business partner serve contacts allegations reported chief compliance officer via addition assess supplier compliance business ethics incident management system human rights standards ssav beims human rights violations especially audit programme suppliers also identified procurement departmentethical business practices human rights roche supplier sustainability audits number supplier audits sustainability audits triggered high conducted contract human rights risk manufacturers sustainability audits findings related ssav audits human rights labour facilities utilities contract research organisations laboratory supplies logistics transportation ssavs per industry construction building temporary labour telecommunication waste management cleaning common critical major findings categories excessive overtime incorrect overtime compensation granted enough days annual leave delayed payment wages improper maintenance hr payroll documentation safety security health environment supplier sustainability assurance visit contents letters shareholders sustainability report contribute corporate governance remuneration report facilities utilities construction building contract research organisations logistics transportation human rightsrelated laboratory supplies findings per industry temporary labour waste management cleaning services telecommunication number findings regarding child labour young workers b number findings regarding forced labour c number findings regarding overtime payments total findings human rights impacts including c ethical business practices human rights roche riskassessed suppliers significant suppliers assessed relation ssav programme successful collaboration business partners avoid negative impacts human rights roche observed findings related working time registration systems appropriate human rights fair labour practices notably within control mechanisms within existing operational logistics industry segment processes well implementation dedicated training managers operational team leaders audits performed within ssav programme raise awareness within area human rights highlighted several situations within logistics labour industry companies introduce manage appropriate policies procedures protect effectiveness efficiency actions rights employees recurring problem lack implemented within cap confirmed appropriate control mechanisms regarding working followup audits independent external auditor conditions especially overtime days truck drivers warehouse workers noncompliances roche aware throughout supply noted final audit report reflected within chain must actively cooperate suppliers corrective action plan cap addressing proper business partners minimise risk noncompliance actions remove especially related human rights fair labour practices time constantly improving cap contained implementation appropriate internal due diligence processes procedures policies systems procedures secure employee guide activities risk analysis beyond rights include implementation electronic tier level significant suppliers assessed riskbased methodology supplier sustainability assurance visits ssavs contents letters shareholders sustainability report contribute corporate governance remuneration report environment roches progressive approach environmental protection management reflects strong commitment risk mitigation intrinsic business environmental protection nothing new roche minimising ecological footprint many years working minimise part commitment sustainable ecological footprint increase use development strive use new renewable resources expanding global sustainable technologies processes minimise business achieve embedded impact environment measure procedures environmental protection impact environment using ecobalance throughout operations metric developed swiss federal office environment want improve roche aims mitigate environmental risks via ecobalance least compared multidisciplinary system prevention report overall improvement successful environmental risk management system ecobalance compared expert teams roche site identify risks achievement reflected improvement develop mitigation plans communicate observed compared policy guidelines employees improvement attributed reduction stakeholders motivate implement phosphorus emissions increased use sustainable necessary measures energy decrease water use approach prevention sense greenhouse gas emissions responsibility methodically pharmaceuticals diagnostics industry approach issues concerning quality productivity contributor global ghg emissions must take costefficiency environmental programme appropriate measures reduce impact roche operational strategies covering climate adheres international agreements define change mitigation reducing greenhouse gas ghg targets schedules reducing emissions emissions increasing resource efficiency paris agreement well national environmental aspects procurement water legislation site level waste management complement strategies setting tangible quantitative ghg emissions integral part roches mediumterm longterm goals environmental impact therefore set ambitious realistic reduction targets line continuously monitor environmental latest climate science committed performance range key performance science based targets indicators kpis gives us greater oversight initiative sbti submit targets control impacts allows us identify approval longterm goal reduce scope areas improvement helping ensure compliance ghg emissions real zero high standards meet objectives means reaching zero operational emissions byenvironment roche key sustainability topics climate change air pollution water circularity expert teams roche site identify environmental risks develop mitigation plans communicate policy guidelines employees stakeholders motivate implement necessary measures contents letters shareholders sustainability report contribute corporate governance remuneration report focusing reduction efforts rather providers meet standards relying carbon offsets shortterm goal ensure compliance inspect operations reduce total scope ghg emissions suppliers make recommendations levels scope improvement event noncompliance emissions decreased due either ask improvements actively increase use sustainable energy monitor support terminate contract scope ghg programme improving data quality value chain emissions significant part roche plays pivotal role advancing healthcare total footprint began developing bringing lifesaving medications treatments decarbonisation roadmap partnering diagnostics millions people worldwide suppliers industry health systems financial amidst pursuit innovation therapeutic institutions accelerating progress breakthroughs crucial prioritise reach net zero emissions sustainable safety wellbeing workforce alongside markets initiative smi health systems taskforce environmental sustainability accurate immediate focus identifying key hotspots reliable employee safety environmental decarbonising healthcare supply chains patient data key enabling ethical sustainable care pathways delivering digital solutions responsible practices sustainable clinical research supplier engagement crucial part approach smi accurate employee safety environmental pharmaceutical supply chain initiative psci performance data help us identify potential risks communicating expectations suppliers hazards implement preventive including emissions disclosure commitment measures reduce likelihood workplace sciencebased targets scope accidents injuries environmental incidents emissions decreased overall emissions also essential demonstrating business flights waste use sold products compliance diagnostic instruments increased reporting period supply chain emissions decreased line last year roche reviewing lower thirdparty spend especially data collection processes part journey covid portfolio due restatement using made significant changes data practices granular activitybased emission factors systems across organisation includes aligning processes platforms enable environmental compliance efficient accurate safety health dedicated team roche employees around environmental data collection efficiency globe identifies potential risks people goods gains allowed us focus workplace environment roches reputation corporate safety initiatives enable people deliver safety security health environmental patient outcomes reduce environmental protection audit team inspects pharmaceuticals impacts time access realtime data diagnostics manufacturing facilities also allowed roche extract meaningful environmental performance implementation insights dynamic way previously environmental policy line legal possible roche plans expand work requirements internal standards expect coming years continuing explore innovative contract manufacturers suppliers service technologies within safety health environmentenvironment roche water consumption noise pollution landfilled waste energy consumption emissions water roche emissions air ecobalance vehicles operate using energy sustainable sources electricity company vehicles look ways reduce energy consumption improve energy efficiency energy use aim using renewable electricity selected types business air travelling natural gas video teleconferencing facilities established sites widely used employees encouraged use trains consolidate several business trips one contents letters shareholders sustainability report contribute corporate governance remuneration report scope scope market based capital goods scope scope scope ghg emissions ghg emissions ghg emissions co co co purchased goods scope scope services scope market based fuel energyrelated activities upstream transportation waste generated operations business travel use sold products direct emissions within operations indirect emissions purchased energy emissions resulting activities within supply chain calculation methodology based ghg protocol following hybrid activitybased approachenvironment roche energy consumption terajoules total scope scope market based energy scope scope market based consumption gjemployee gj gigajoule halogenated hydrocarbons tonnes inventory releases global inventory including chugai genentech ventana includes data additional roche sites well wider scope halogenated hydrocarbons previous years emissions air tonnes vocs particulates nitrogen oxides sulphur dioxide volatile organic compounds water usage discharge water withdrawn million water consumed million organic matter discharged waterways treatment heavy metals discharged waterways treatment kg increase heavy metals due additional reporting iron manganese landfilled incinerated waste tonnes nonhazardous hazardous one affiliates reevaluated waste disposal classification resulted increase reported numbers increase hazardous waste due reallocation electronic waste hazardous waste environmental data spark therapeutics flatiron health included roche environmental results contents letters shareholders sustainability report contribute corporate governance remuneration report global citizenship communities arts culture environment education philanthropic programmes united one goal partnering create lasting impact mean good global corporate chf million donations supported citizen roche means contributing making childhood development education projects difference communities live last years work help make healthier resilient sustainable aim create lasting employee volunteering vital philanthropic impact across philanthropic endeavours efforts secondment programme draws upon broad pool employee specialists skillsbased cant achieve alone moment volunteering nongovernmental organisations first ventured philanthropy ngos across two domains science education international committee red cross icrc humanitarian health one initiative saw back collaborated trusted members gps digital excellence partners today fastchanging external team around world volunteer environment partnerships important hours swisscontact ngo fostering ever increasingly work integrated sustainable development developing countries way several stakeholders insights provided roche team enabled digital strategy help swisscontact grow established policy ensure reach reputation projects endorse meet specific quality innovation sustainability criteria strictly rapid collaborative disaster response adhere high integrity standards set important ever work closely roche group code conduct sustainability affiliates identify best ways support group reporting system gaia ensures internal local efforts relief organisations help documentation monitoring assets spent disasteraffected communities rebuild prepare philanthropy future drove many projects potential earthquake hit areas trkiye syria lasting impact across four key pillars community february roche joined international partners environment humanitarian social science help ensure uninterrupted access healthcare education arts culture trkiye helped establish six field health units four cities fully equipped family health community environment centre adyaman one hardesthit cities roche childrens walk biggest employee syria supplied two highly specialised mobile engagement philanthropy initiative health units celebrated th anniversary gorochecomdonationsandnoncommercialsponsorship see feature anniversary reportglobal citizenship roche key sustainability topics sustainable health systems communities stakeholder engagement roche continents programme students participate workshop sustainable colour dyeing atelier luma design research programme luma arles france contents letters shareholders sustainability report contribute corporate governance remuneration report since roche supported icrc change sustainability human capital input drive improve access clean water essential artists scientists severin schwan services hundreds thousands vulnerable chairman roche board directors andr people mali many cut humanitarian hoffmann vicechairman hans clevers head organisations total people roche pharma research early development received improved access drinking water inspired engaged students discussions contributed similar projects science sustainability importance ethical icrc since across several countries responsible business including pakistan ethiopia liberia uganda burundi eritrea guinea parallels arts science also apparent tenyear anniversary roche science education young commissions partnered passionate nurturing next lucerne festival commission new works generation scientific leaders collaborative young composers paired two environment support international scientists eoin oconnor shanon seger chemistry olympiad icho annual competition visited roche labs young composers worlds talented chemistry students david moliner hovik sardaryan premiered competition held switzerland incredible composition kkl luzern concert first time since began proud hall like work roche young vivian michael huber firstplace winner commissions shows working together across completing apprenticeship roche disciplines perspectives countries leads field synthesis creativity innovation intersection science arts explored opening continue champion education programmes dialogue hans clevers composer train next generation healthcare welcome speech provided teresa providers vital world experiencing health graham ceo roche pharmaceuticals system labour shortages fund wide range scholarships emerging markets providing roche celebrate multiculturalism value education training new nurses speaks diverse inclusive training oncology nurses indonesia health culture proud support workers lab technicians culturescapes biennial festival promoting arts crosscultural dialogue networking arts culture theme sahara roche played integral roche long tradition cultivating role supporting festival including hosting interdisciplinary exchanges foster creativity opening event dance production called innovation example roche continents c la vie serge aim coulibaly renowned programme brings together talented international dancer choreographer burkina faso students studying european universities dance like event tribute pluralism immersion diverse world arts science uniqueness life events offer roche continents held arles france unique opportunity employees partnership luma arles centre arts community experience rich artistic culture focus climate cultural diversity cherishglobal citizenship roche sites countries joined roche childrens walk years chf millions raised projects supported total attendance employees incl enduring alliances longstanding partners drive sustainable impact roche commissions roger federer foundation renowned composers paired roche children enrolled scientists featured lucerne festival school readiness initiative years partnership roche unicef culturescapes children received educational support arts culture celebrations fostered dialogue diversity inclusion children accessed early childhood development programmes illustrative map participating sites exhaustive contents letters shareholders sustainability report contribute corporate governance remuneration report information security roche security goes beyond compliance strategic advantage central goal developing medicines diagnostics insights help people live longer better lives work revolves around data integrity jurisdictional data privacy regulations data must protected information hipaa us gdpr eu security allows us proceed swiftly developing medical advancements unhindered potentially making security simple damaging cyberattacks take companies cybersecurity shared responsibility offline seconds minutes even months also work ensure researchers partners preserves security partners healthcare operate without constant fear security organisations collaborate breaches tim ehrhart roches chief information third parties whose systems know security officer puts candidly security compromise devices products teams goal delightfully boring importantly patient data inconspicuous background creating environment employees partners patient safety data privacy focus need prioritise rather patient safety data privacy worry cyber safety utmost importance roche comply applicable global regional local laws security approach enables safe collaboration regulations standards policies contractual anywhere time many organisations obligations robust list certifications require employees switch laptops provides assurance roche maintaining travelling internationally forbid use comprehensive information security management personal devices believe restrictive policies system strong security governance stateof complicate work employees without offering theart risk management effective security controls meaningful boost safety particularly todays processes appropriate information postcovid era people demand deserve security operations commitment levels freedom connect wherever may management high employee awareness achieved taking necessary measures best practices cybersecurity data ensure simple user experience embedding privacy protection safety design builtin security data privacy fundamentally safe design navify digital solutions securely integrate data informatics system fundamentally safe across care settings connecting healthcare design practical terms minimise usage community accelerating access innovation virtual private networks using cloud computing insights employ multilayer security compartmentalise data follow policy stateoftheart controls protect customers justintime access system application patients sensitive data complying access granted predetermined periods timeinformation security roche key sustainability topics compliance business ethics data governance privacy cybersecurity security policies structures people roche employees around world along partners stakeholders work together protect integrity confidentiality systems data contents letters shareholders sustainability report contribute corporate governance remuneration report asneeded basis help minimise risk growing security capabilities inhouse breach occur contained therefore fully integrated members organisation pose threat wider systems culture roche information security experts safety design means better equipped dedicated healthcare mission handle potential breaches cause minor roche employee bring diverse array inconvenience rather major incident experience across telecommunications approach relieves users much security finance government healthcare industries burden possible also sustainable embedding security business strategy requiring fewer total devices lowers means unlike many competitors environmental impact result costeffective outsource majority information resilient security posture supports sustainable security organisation instead prioritise innovation empowers workforce growing security capabilities inhouse adaptable within secure environment cultivating supportive fulfilling work environment increase ability attract retain top developing empowering people security talent says tim security policies structures people roche employees constantly testing improving around world along partners threats constantly evolving stakeholders work together protect integrity team constantly improving security posture confidentiality systems data using multipronged approach conduct information security awareness training roche penetration tests web security vulnerability tests privacy awareness training mandatory daily network perimeter tests benefit employees additionally invest heavily external expertise strong continuous development opportunities network partners including security experts technical experts stay ahead industry trends healthcare government technology vendors constantly evolving cyberthreats helps private entities ensure prepared proactive mitigating threat risksinformation security roche vendor security privacy assessments completed information security privacy risk assessments performed security incidents resolved information security critical vulnerability alerts released bug bounty reports received remediated employees feel aware contributing towards preventing security risks cyber threats usd rewards given external security researchers compliance certifications certifications patient safety privacy utmost importance iso roche comply applicable global regional iso local laws regulations standards policies soc type certifications right provide assurance roche cyber essentials uk maintains comprehensive information security management hitrust ism framework strong security governance state oftheart risk management effective security controls processes appropriate information security organisation operations contents letters shareholders sustainability report contribute corporate governance remuneration report independent practitioners limited assurance report selected nonfinancial information corporate governance sustainability committee roche holding ltd basel engaged corporate employee health safety graph governance sustainability committee report perform assurance procedures provide limited roche ecobalance energy use assurance selected nonfinancial information selected types diagrams including greenhouse gas ghg emissions report roche holding ltd consolidated key figures tables graphs subsidiaries roche group period pages except scope capital january december disclosed goods purchased goods services annual report report fuel energyrelated activities upstream transportation waste generated operations scope subject matter use sold products assurance engagement relates limited level assurance selected nonfinancial criteria information including ghg emissions selected nonfinancial information january december disclosed including ghg emissions prepared report corporate governance sustainability committee roche holding ltd based following selected nonfinancial information document nonfinancial reporting indicators including ghg emissions published definitions scope suitable criteria report within scope limited assurance available roche website engagement gorochecomnonfinancialreportingscope following people key figures material inherent limitations aspects disclosed report accuracy completeness selected number employees expressed ftes nonfinancial information including parttime fulltime employees well ghg emissions subject inherent limitations employees divisionoperating divisional given nature methods determining group odg diagram calculating estimating data addition report greenhouse gas quantification subject share women executive positions inherent uncertainty incomplete graph report scientific knowledge used determine factors related values needed combine emissions following safety security health different gases assurance report environmental protection key figures therefore read connection including ghg emissions scope document nonfinancial reporting indicators scope resulting business travel definitions scope used roche group material aspects disclosed report definitions procedures well pricewaterhousecoopers ag birchstrasse postfach ch zurich telephone wwwpwcch pricewaterhousecoopers ag member global pricewaterhousecoopers network firms separate independent legal entityindependent practitioners limited assurance report roche related thirdparty guidelines used present practitioners responsibility selected nonfinancial information responsibility perform limited assurance engagement express conclusion corporate governance sustainability selected nonfinancial information including committees responsibility ghg emissions roche group disclosed corporate governance sustainability report conducted engagement committee roche holding ltd responsible accordance international standard preparation presentation non assurance engagements isae revised financial information including ghg emissions assurance engagements audits accordance document non reviews historical financial information financial reporting indicators definitions international standard assurance engagements scope responsibility includes design assurance engagements greenhouse implementation maintenance internal gas statements isae issued control system related preparation international auditing assurance standards selected nonfinancial information free board standards require plan material misstatement whether due fraud perform procedures obtain limited assurance error furthermore corporate governance whether anything come attention sustainability committee responsible causes us believe selected selection application document nonfinancial information including ghg basis preparation nonfinancial information emissions prepared material aspects adequate record keeping accordance document nonfinancial reporting indicators definitions scope independence quality management independent roche holding ltd based risk materiality considerations accordance international code ethics performed procedures obtain sufficient professional accountants including appropriate assurance evidence procedures international independence standards issued selected depend assurance practitioners international ethics standards board judgement limited assurance engagement accountants iesba code fulfilled isae revised isae ethical responsibilities accordance iesba substantially less scope reasonable code founded fundamental principles assurance engagement relation integrity objectivity professional competence risk assessment procedures including due care confidentiality professional behaviour understanding internal control procedures performed response assessed pricewaterhousecoopers ag applies international risks consequently nature timing extent standard quality management requires procedures gathering sufficient appropriate firm design implement operate evidence deliberately limited relative system quality management including policies reasonable assurance engagement therefore procedures regarding compliance ethical less assurance obtained limited assurance requirements professional standards engagement reasonable assurance applicable legal regulatory requirements engagement contents letters shareholders sustainability report contribute corporate governance remuneration report performed following assurance procedures believe evidence obtained among others sufficient appropriate provide basis r eview application roche group conclusion guidelines reviewing application roche group conclusion selected nonfinancial reporting guidelines based work performed nothing per document nonfinancial reporting come attention causes us believe indicators definitions scope selected nonfinancial information including ghg emissions roche ite visits management inquiry group period january visiting selected pharmaceuticals december disclosed report diagnostics sites china germany italy prepared material respects accordance usa selection based quantitative document nonfinancial reporting qualitative criteria indicators definitions scope interviewing personnel responsible internal nonfinancial reporting data collection intended users purpose report sites visited group level report prepared determine understanding application corporate governance sustainability roche groups nonfinancial reporting guidelines committee roche holding ltd solely per document nonfinancial purpose reporting selected reporting indicators definitions scope nonfinancial information including ghg emissions disclosed report ssessment key figures purpose giving conclusion performing tests sample basis evidence accept assume responsibility legal otherwise supporting selected people key figures accept liability connection concerning completeness accuracy adequacy purpose report including consistency conclusion may used person report shown whose hands r eview documentation analysis relevant may come persons shall entitled policies principles rely conclusion reviewing relevant documentation sample basis including roche group nonfinancial permit disclosure report full reporting policies management reporting combination suitable criteria structures documentation enable corporate governance sustainability committee demonstrate ssessment processes data discharged governance responsibilities consolidation commissioning independent assurance reviewing management nonfinancial report selected nonfinancial reporting processes selected people information including ghg emissions key figures without assuming accepting responsibility assessing aggregation process data liability third parties part roche group level fullest extent permitted law acceptindependent practitioners limited assurance report roche assume responsibility anyone corporate governance sustainability committee roche holding ltd work report pricewaterhousecoopers ag bruno rossi raphael rutishauser zurich january maintenance integrity roche holding ltds website content responsibility corporate governance sustainability committee work carried assurance provider involve consideration maintenance integrity roche holding ltds website accordingly assurance provider accepts responsibility changes may occurred specified nonfinancial information suitable criteria since initially presented website contents letters shareholders sustainability report contribute corporate governance remuneration reporthow contribute roche contribute commitment innovation collaboration bring meaningful change patients people communities across globe stories behind advancements capture reach impact peoples work contents letters shareholders sustainability report contribute corporate governance remuneration report roche patient expert since antoine helped roche colleagues better understand experiences people multiple sclerosis mshow contribute roche sharing journey multiple sclerosis antoine helps us improve care people ms antoine learned relapsing perspective contributed valuable outcomes remitting multiple sclerosis felt shocked also feedback ensured patientfacing relieved sought help losing vision materials easy understand roches one eye feeling pins needles head integrated strategic plan isp ms focused suspecting might fatal illness felt happy meeting patient needs antoine great person brain tumour recalls team brought lived experiences also broader perspective decided keep diagnosis private patient community said marco parisi engineering job medical devices plant led development isp ms native france kept smile face even helped us build strategy based struggled focus steady going needs patients win ms looks like stairs came time annual review boss told performance declined company wanted let go antoines voice also helped roche colleagues didnt know ms antoine recalls better understand experiences people cracked cried ms valued addition training provide ocrevus ms therapy experience early antoines journey ms immunemediated disease affects true inspiration everyone million people leading cause non antoine joined roche work placement traumatic disability young people antoine organised governmentrun scheme since embraced transparency today one provides reintegration opportunities members carering internal community financial support people disabilities employees also patients caregivers roche committed advancing inclusion regularly shares details life ms people disabilities valuable help roche improve delivery care carering pledge antoines placement facilitated community designed create safe trusting rocheability network promotes space members share experiences disability inclusion one first connect contribute projects related kind roche since consulting relevant disease areas us four hours week feels well enough attending rehabilitation collaborating patient communities including ms patient organisations patients families etc enables us better understand unmet needs patient team something unique cocreate solutions support personalised across industry says christine eighteen healthcare early stage drug development roches global patient partnership leader ms delivery care works closely antoine im proud roche provides people living diseases like ms roche patient expert since antoines opportunity continue work im grateful courage honesty passion sharing patient value add business gorochecomatlasofmsnumberofpeoplewithms contents letters shareholders sustainability report contribute corporate governance remuneration report working roche given sense relief ms may evolving secondary progressive dont feel handicap says ms characterised gradual worsening antoine patient expert talking symptoms definite periods remission ms using brain help people worries treatment options really important help people better limited type ms understand disease response antoines emerging cognitive setbacks along way challenges roche colleagues implemented antoines ability confront disease strategies ensure track tasks positivity encouraged us work requires rehabilitation lastminute commitment improving lives living timeintensive roche adapts accommodate ms first diagnosed antoine absence always remain flexible met neurologists physiotherapists organisation availability changes psychologist help less visible depending health health always effects disease ms linked priority says christine physical symptoms antoine says may see struggling walk losing balance readapting new reality struggling fatigue cant see mental prioritise aspects health control state fact forget things easily antoine recently given alcohol changed effects disease like ms multifaceted diet daughter family still work still lots things try focus like people ms antoine spent early ive lost part journey working doctors find treatment worked best learned antoine continues advance roches selfadminister injections act wasnt easy understanding life ms enabling better accept frequent injection patient care valued colleague inspires constant reminder ms antoine commitment supporting peers says approaches setbacks difficult days ability adapt changing life positivity daughter dont want readaptation important word show papa sick papa tired papa ms patients since ive condition ive struggles lots things even bad working readapt new night always greet smile says today antoine says become antoine adjusted life ms moved comfortable asking help new basel wife katie found work roche perspective life ms puts things began looking work started seeing perspective dont sweat small stuff changes new medical team recently however antoine way thinking behaviour changed medical team begun suspect behaviour drastically better thinkhow contribute roche antoine continues advance roches understanding life ms enabling better patient care feedback ensured patientfacing materials easy understand contents letters shareholders sustainability report contribute corporate governance remuneration report human model systems related cuttingedge technologies potential reduce reliance animal testing significantly speed drug development processhow contribute roche accelerating drug discovery development institute human biology inflection point healthcare human one key area interest ihb organoids model systems miniature simplified versions tiny tissue cultures mimic properties human tissues organs poised transform vivo organs derived patients way discover develop new therapies tissues enabling individualised diagnosis although still infancy technology treatment applications technology potential reduce reliance animal testing farreaching example cystic fibrosis centres significantly speed drug development netherlands beyond routinely use process without sacrificing patient safety organoids determine patient eligibility cystic fibrosis therapies work led hans clevers institute human biology ihb launched head pred roche brings considerable may latest example roches expertise organoids ihb commitment advance human model systems institute combines best exploratory research roches pred already success translational power industry solve organoids testing anticancer drugs using reallife challenges drug discovery organoids assess drug response scientists development established roche pharma progressed drugs clinical trial stage research early development pred innovation without animal testing engine ihb provides platform cutting edge collaboration among experts exploratory capacity create sustainable solutions biology biomedicine engineering computational patients safer effective data science institute world personalised key differentiator human model unites areas one roof partnerships systems potential transform healthcare academic institutions including swiss still way go reach federal institute technology eth zurich ensure widespread application ihb play key foster next generation translational role advancing technology contributing bioengineering talent equip address longterm vision revolutionise industry drug future healthcare challenges discovery development contents letters shareholders sustainability report contribute corporate governance remuneration report mystoryforchange illustrations capture experiences challenges women world encountered throughout healthcare journeyhow contribute roche closing gaps womens health equity xproject long women overlooked chromosome historically overlooked healthcare systems see men default project grown number initiatives research womens health chronically spanning health technology financing teresa underfunded leaving women facing inequities graham ceo roche pharmaceuticals together treatment access care women passionate colleagues major likely misdiagnosed heart driving force project attack example disparities bigger women colour black women suffering outside roche momentum also building higher mortality breast cancer compared march united nations population white women fund unfpa launched equity alliance roche founding member global recognition systemic blindness commitment brings together leaders private experiences needs women catalysed sector academia government close gender movement amplify empower womens equity gaps voices mystoryforchange campaign roches xproject aims since technology key launch early women femtech plays crucial role prevention around world shared stories diagnosis management womens diseases healthcare experiences roche looks harness power innovative technologies improve patient outcomes endometriosis left undiagnosed including specifically designed collect five years time found womens health data partnership microsoft mass twice size uterus shared one developed tool uses artificial intelligence woman mother biracial medical doctor cloud technologies improve breast cancer grossly dismissed peers took hours diagnosis middle east accuracy advocating received lifesaving continue support femtech innovations example care said another mothers heart attack participating annual femtechnology summit brings together leaders across industry together driving change techeva acceleration programme roche longstanding history womens womens health startups health pioneering diagnostics treatments conditions primarily address women womens health niche issue women xproject represents continued commitment better society amplifying ongoing initiative aiming close gaps womens voices advancing genderinclusive womens health partnerships funding solutions health technology financing action create better health outcomes provide better outcomes even people everyone x xproject represents female around world w e use terms woman women refer people biologically two x chromosomes xx however inclusivity core xproject recognise individuals may identify female respect gender identities diverse striving equitable health system rochecomxprojectxstoriestechnologyforwomenshealth contents letters shareholders sustainability report contribute corporate governance remuneration report last years ieepo become cornerstone engagement worldwide patient communityhow contribute roche engaging patient community thinking globally acting locally patient partnership model prioritises central vision ensuring patients integration patient insights feedback seat decisionmaking tables early latestage research believe informed active voice shape patient voice greatest impact healthcare delivered across globe value work extends well beyond development setting key helping core mission ieepo humanise shape effective policy well healthcare healthcare coordinated action five systems key topics improving health literacy work closely connected mission advocating universal health coverage help patient communities play influential geographies markets purposeful role healthcare mission improving collection utilisation championed last years health data support decisionmaking international experience exchange patient focusing prevention cure organisations ieepo model prioritising diversity equity inclusion proud ieepo become healthcare cornerstone engagement worldwide patient community platform enables us topics complex help patient organisations identify synergies different implications every country markets programmes support know sharing knowledge experience build capabilities amplify voice learnings within patient community collaborate urgent topics ultimately drives change thinking globally goal making healthcare accessible built collective capacity act locally empowering every person regardless age patient community sex gender race ethnicity socioeconomic status stakeholders participating platform health literacy geography take control related events countries ieepo health contents letters shareholders sustainability report contribute corporate governance remuneration report roche bold ambition radically improve breast cancer diagnosis treatment eight ten women africa survive five years diagnosishow contribute roche supporting breast cervical cancer services africa breast cervical cancer currently constitute services six sites across kenya cte divoire half cancer burden women sub zimbabwe saharan africa women cancers african countries diagnosed initiative includes health promotion late stage five ten women diagnosed screening early diagnosis treatment well breast cancer african country survive general primary care screening five years compared nine ten highincome noncommunicable diseases early detection countries services integrated existing cervical cancer screening clinics ensure old roche identified breast cancer priority new systems unified aim provide condition addressed part long integrated holistic system healthcare term strategy africa believe contribute addressing burden support people disease may also breast cervical cancer african region support delivery noncommunicable diseases support health equity strategies initiative also seeks increase healthcare workers ability provide cancer care within roche bold ambition radically improve communities training supply breast cancer diagnosis treatment deliver necessary equipment eight ten women africa survive five essential supplies support women primary years diagnosis achieve monumental healthcare level ambition roche working consortium influential stakeholders uniting governments programme marks exciting tangible civil society development finance institutions step path true health equity africa private sector entities multilateral organisations demonstrates new way public community leaders healthcare professionals private sector work together drive real bringing expertise resources change within healthcare systems said maturin fight tchoumi roche pharma international area head africa time launch september world health organization regional office africa announced pilot collaborations absolutely vital enable support better access breast cervical longterm sustainable access healthcare cancer services three african countries roche goes screening diagnosis supporting regional office africa treatment roche proud support funding provide integrated breast cervical regional office africa initiative contents letters shareholders sustainability report contribute corporate governance remuneration report roche conducting clinical trials years continues work across africa close representation gaps trial research datahow contribute roche working towards healthier future africa worlds fastestgrowing population addition african genomics program birthplace humanity yet less expanding equitable data access africa human genome data comes people accelerating research number african descent important population initiatives underway enhance capacity also underrepresented clinical trials reducing continent genomics ecosystem two opportunities scientists research diseases key programmes initiated include together develop medicines equally effective change collaborative effort several across global populations industry peers meharry medical college create largest african genomic database sciencedriven healthcare company striving date comprising samples improve health outcomes patients roche people african descent us africa committed addressing barriers prevent globally available data increase opportunities people accessing quality healthcare one discover new human biology better diagnose key ways work ensuring prevent treat disease additionally inclusion increasing representation discover south africa collaborative research historically excluded populations research initiative access analyse health development help optimise health outcomes genetic information patients patients worldwide south africa commitment africa example roche time building capacity conducting clinical trials years next generation african scientists offering continues work across continent fellowships focused clinical pharmacology diaspora close representation gaps trial pathology human genetics research data growing momentum across continent powered african scientists understand still much work ahead broad network partners including ngos committed continue improve academia public sector private sector inclusion understudied patients clinical including roche partnerships research generating data enables us recent advances technology closer assess safety efficacy innovations ever closing data gaps ultimately underrepresented demographic groups working towards healthier future roche reducing barriers equitable care diverse proud commitment africa taking patients everywhere part momentous push forward contents letters shareholders sustainability report contribute corporate governance remuneration report roche committed helping improve global diagnostics capacity enable access affordable highquality healthcare services people around worldhow contribute roche improving access diagnostics strengthened labs diagnostics essential decisionmaking hospital spend roche committed along every step patients health wellness helping improve diagnostics capacity around disease journey diagnostic test alone world investing laboratory infrastructure help clinicians change course someones innovations increase lab efficiency healthcare experience life leader also continuing support programmes diagnostics roche committed train new laboratory professionals enhance advancing solutions support clinicians skills already working lab yet making critical decisions patients many countries laboratory capacity health also improving way tools meet current needs let alone future integrated health systems around world challenges greater lowincome rural communities thought people healthcare professionals increasingly depend low middleincome countries lmics laboratory tests make diagnostic little access lifesaving diagnostics many treatment decisions billion tests countries lack integrated laboratory performed roche diagnostics platforms network provide highquality accessible role lab goes far beyond efficient lab testing services actual test empowering doctors make right decisions right time giving people may roche welcomed adoption greater control health wellbeing resolution strengthening diagnostics helping payers policymakers use resources capacity world health assembly wha efficiently resolution supports diagnostics core pillar universal health coverage uhc guarantee stronger labs help healthcare systems people access affordable highquality make savings routine management health services adoption resolution population health like cancer cardiovascular represents important step towards increasing disease dementia investing also global access novel highmedicalvalue helps reduce costs prepare future diagnostics solutions public health crises like pandemics study germany found pcr antigen testing added momentum wha resolution covid pandemic helped reduce incidence roche partnering stakeholders infection resulting fewer deaths advocacy publicprivate partnerships eur billion healthcare cost savings implement drive greater diagnostics capacity globally focusing lmics access insufficient resources underfunding two critical one example partnership greatest challenges facing labs today despite global fund helps improve diagnosis importance laboratory systems lack hiv tuberculosis lmics building local political financial support needed diagnostics capacity continue advocate estimated although lab results drive around political commitment strengthening laboratories clinical decisions labs account key driver achieving uhc gorochecomimpactcoronatestingeconomyandhealthcare contents letters shareholders sustainability report contribute corporate governance remuneration report roches yearslong engagement uruguays haemophilia stakeholders instrumental establishing foundation universal coveragehow contribute roche innovative novel access solutions treatment option uruguay hemlibra approved countries foundation universal coverage people living haemophilia inhibitors originally expected achieved countries people inhibitors negotiations accelerated young boy increase access innovative treatment options haemophilia wrote countrys president patient organisations treatment centres describing life lacking access treatment pharmaceutical companies must work together asking therapy every child governments make clinically informed decisions haemophilia needed treatment uruguay help improve lives patients innovate solution roche put together team colleagues access pricing medical latin america roche spent years listening compliance haemophilia community better understand needs provide integral solutions thus expanding access innovative treatment considered trusted ethical partner options budget constraints required provided solutions based continuous innovative payment model unwavering collaboration different sectors resulted commitment transparently ethically firstofitskind agreement uruguay offer cocreate model patient organisation coverage treatment option paediatric physicians opinion leaders healthcare providers patients adults inhibitors factor viii payers government roches yearslong engagement uruguays mark th anniversary roche haemophilia stakeholders including supporting uruguay proud trusted reputation haemophilia patient association develop weve maintained country enabled population census instrumental establishing us bring innovative treatments people contents letters shareholders sustainability report contribute corporate governance remuneration report roche expanded architectural focus include sustainable construction principles aiming set benchmark industryhow contribute roche taking holistic approach sustainable building construction construction sector accounts around energy fostering environment boosts global waste half worlds energy employee efficiency prioritises health consumption recognising role global entity comfort evaluations revealed sustainable roche determined help mitigate impacts buildings roche require average less building rich tradition architectural energy compared standard buildings users excellence roche expanded focus include show higher productivity sustainable construction principles aiming set benchmark industry collaboration central roches vision sustainable construction example work sustainability construction necessity science based targets initiative sbti set roche risen challenge using ghg reduction targets line climate science novel sustainable construction methodology roche demonstrates commitment reducing seamlessly integrated sustainable building impact underscores broader significance ethos approach promotes urgency sustainable construction todays sustainability reduced environmental world sustainable construction approach impact also encourages productivity competitive differentiator helps us generate community contribution longterm value three key pillars underpin roches sustainable one example commitment reuse construction approach kids initiative collaboration canton baselstadt bern university applied pplying circularity principles reduce waste sciences site basel testing reuse increase resource reuse recycling old building components build two kindergartens cutting greenhouse gas ghg emissions city innovative project aim reducing buildings carbon footprint demonstrates commitment sustainability esigning enhance productivity also contributes wellbeing connection wellbeing buildings occupants community roche developed software tool make building architectural heritage roches possible carry construction projects holistic approach sustainable construction compliance relevant sustainable positions us role model industry construction requirements tool evaluates focus environmental protection community buildings entire sustainability performance engagement buildings stand symbols planning stage end roches values one marking step towards life new buildings designed conserve circular decarbonised economy contents letters shareholders sustainability report contribute corporate governance remuneration report funds roche employees raise roche childrens walk go react supports early childhood development education partners like selam childrens village ethiopia left unicef projects right unicefuniose around worldhow contribute roche twenty years impact children every child right education girls development education efforts around malawi miss days school year world beginning partnership average due stigma discrimination unicef supported access education face menstruating children disadvantaged backgrounds total children benefitted help keep girls school unicef runs unicef educational programmes across programme create awareness menstrual ethiopia malawi nepal philippines health help reduce stigma discrimination partners include childs dream organisation roche employee action charity trust working improve education access children react independent entity funded cambodia selam charity supports roche employees childrens walk orphans ethiopia roger federer supported unicef programme since foundation supports range childhood since programme educated development initiatives school community members menstrual health hygiene provided girls roche employees making possible reusable pads supplies collaboration incredible organisations possible employees dedication dont view menses curse anymore said childrens walk alone one young women received education employees participated across roche menstrual health programme sites countries raising chf million schoolmates freely talk support everyone learn peace last years leading roche fundraisers contributors experienced work malawi one example many firsthand impact funds raised projects supported react charity rooted childrens walk ambassadors tradition philanthropy reflects six ambassadors visited cambodia see commitment act global citizens contributing work childs dream done improve school local efforts build stronger healthier infrastructure create computer facilities communities provide highschool scholarships eight ambassadors travelled ethiopia see proud celebrate years selam childrens village supported react roche childrens walk years since fund orphan homes youth roche employees participated vocational training malawi visit event raising chf million children essential educational projects need led unicef partnering progress stories shared ambassadors partners since childrens walk started especially children serve remind us react partnered range nonprofit incredible impact education organisations support early childhood childrens lives contents letters shareholders sustainability report contribute corporate governance remuneration report aspire deliver security privacy regulators require customers expect patients deservehow contribute roche privacy security regulators require customers expect patients deserve believe data integral improving lives define responsible tasks patients physicians treat ensure smooth efficient operation roche security health systems care teams partner closely follow governance risk focused strengthening zerotrust network management processes ensuring security privacy refining sharedresponsibility model help end end protect data enable entire organisation achieve mission patients security experts ensure effective vulnerability need next incident management promote security privacy awareness supported training zerotrust networking hold partners vendors industrys historical security model high standards set compared castle moat inside rigorous assessment process mitigate risks assumed safe dangers ensure partners meet stringent cybersecurity kept outside unfortunately model never compliance requirements finally report really worked attack one computer could product security privacy integrate put everything risk attacker customer feedback product requirements got past moat chance take whole castle solution problem model looking ahead called zerotrust networking assumes every todays world digitally connected activity comes level risk ever comes network fragility device could attacked misused attacks become sophisticated proliferation connected devices increased instead assuming bad actors make across threat surface put terms castle moat intrinsically trusting corporate moat castle stores treasure network model doesnt trust networks invaders learned swim moats instead trusts identities means make water level dropping sure know accessing data benefit approach event achieve mission environment weve breach damage contained compromised traded castle moat model zerotrust device much less likely pose threat networking shared responsibility company large zerotrust attackers trying sensible thoughtful approach balance breach castle get stuck stables realities todays modern workforce pragmatic security approach understands sharedresponsibility model threat landscape user behaviour allows roche cybersecurity shared responsibility us focus drives us day sharedresponsibility model clearly patients need next contents letters shareholders sustainability report contribute corporate governance remuneration reportcorporate governance roche corporate governance principles board directors corporate executive committee group structure shareholders capital structure board directors corporate executive committee remuneration shareholdings loans participatory rights shareholders change control defensive measures relationship statutory auditors relationship independent proxy information policy chief compliance officer compliance officers network nonapplicabilitynegative disclosure contents letters shareholders sustainability report contribute corporate governance remuneration report principles business activities focus sustainable value relevant corporate governance requirements creation innovation management culture particular applicable laws swiss stock conforming recognised standards good exchange six swiss exchange directives corporate governance policy transparent swiss code best practice corporate communication embody roches corporate governance promulgated swiss business governance principles build basis federation economiesuisse companys internal successful implementation roches commitment governance framework particularly articles serving stakeholders incorporation bylaws embodies principles needed ensure companys strong board directors represents businesses managed supervised interests shareholders manner consistent good corporate governance stakeholders highly skilled managers including necessary checks balances act integrity extremely important printed annual report contains selected links roche ranked one top three roche website httpswwwrochecom sustainable healthcare companies readers thus provided snapshot pharmaceuticals index dow jones company reporting date also sustainability indices djsi th year directed sources consult running recognition based indepth time uptodate information corporate analysis economic social environmental governance roche whereas annual report performance sustainability core covers single financial year ending december business practices award reflects website contains information commitment running business way permanent nature well latest roche news ethical responsible creates longterm value companys articles incorporation bylaws stakeholders curricula vitae current former members board directors corporate executive corporate governance report sets committee published website status structures processes rules roche per end term reporting date takes basis wellfunctioning corporate december year least last governance roche complies ten years httpswwwrochecomaboutgovernancecorporate governance roche annual general meeting annual general meeting board directors board directors board committees board committees chairmansnomination committee remuneration committee corporate governance sustainability committee audit committee corporate executive committee corporate executive committee ceo roche ceo roche ceo roche chief financial chief people group pharmaceuticals diagnostics information officer officer enlarged corporate executive enlarged corporate executive committee committee gred pred pharma partnering communications general counsel global product development corporate strategy sustainability contents letters shareholders sustainability report contribute corporate governance remuneration report board directors review agm review reporting year chair roches nowresigned chairman organising meeting immediately following dr christoph franz th ordinary annual agm board directors determined general meeting agm roche holding ltd structure composition remaining held march first time since committees shown see also without covid restrictions board directors corporate shareholders attending person executive committee successor dr christoph franz shareholders outlook agm elected dr severin schwan member march forthcoming agm board directors member since board directors nominates dr severin schwan new chairman board directors chairman reelection term one year provided articles incorporation time election board directors nominates dr severin schwan resigned member remaining members board directors corporate executive committee member since reelection ceo roche group since moreover board directors nominates furthermore agm reelected andr hoffmann andr hoffmann dr jrg duschmal anita hauser dr jrg duschmal dr patrick frost anita hauser prof dr richard p lifton reelection prof dr richard p lifton dr jemilah mahmood remuneration committee agm bernard poussot dr claudia suessmuth dyckerhoff members board directors board directors nominates testaris ag term one year provided articles election independent proxy agm incorporation period conclusion ordinary agm shareholders moreover prof dr akiko iwasaki dr mark schneider elected new members board directors term one year addition agm reelected andr hoffmann prof dr richard p lifton bernard poussot elected dr jrg duschmal anita hauser members remuneration committee term one yearcorporate governance roche board directors board committees board directors chairmansnomination committee board committees remuneration committee corporate governance sustainability committee audit committee contents letters shareholders sustainability report contribute corporate governance remuneration report board directors members nationality malaysia france austria female switzerland male us germany years years years years years years age tenure average tenure years incl dual citizen triple citizen calculated year first election corporate governance roche non executive committee composition membership dependent name year birth nationality chair member function first elected board directors dr severin schwan ch de e chairman member chairman andr hoffmann representative ch c e g vice shareholder group pooled voting rights chairman dr jrg duschmal representative ch b c e g member shareholder group pooled voting rights dr patrick frost ch b e g member anita hauser ch c e g member prof dr akiko iwasaki us e g member prof dr richard p lifton us c e g member dr jemilah mahmood e g member bernard poussot us fr c e g member dr mark schneider us de b e g member dr claudia suessmuth dyckerhoff de b e g member secretary perolof attinger board directors corporate governance sustainability committee b audit committee c remuneration committee chairmansnomination committee e nonexecutive director f executive director currently member g independent member board directors committee chairperson roches board directors independence definition based definition swiss code best practice corporate governance economiesuisse see httpswwweconomiesuissechsitesdefaultfilespublicationsswisscodeewebpdf complemented specific preceding criteria see httpswwwrochecomabout governanceboardofdirectors members board directors cvs mandates detailed information available follows current members httpswwwrochecomaboutgovernanceboardofdirectors b former members least last ten years httpswwwrochecomaboutgovernanceecbodformer c information reporting date december year least last ten years httpswwwrochecomaboutgovernancearchivformercvs information members board directors shown accordance directive information relating corporate governance dcg httpswwwseragcomdam downloadsregulationlistingdirectivesdcgenpdf also specifically includes mandates accordance article e article para point federal act amendment swiss civil code part five code obligations co may carried comparable positions undertakings commercial objects rules mandates applying members board directors corporate executive committee accordance articles incorporation roche holding ltd httpsassetscwprochecomfxbberochestatutenenpdf explained board directors corporate governance b udit committee c r emuneration committee chairmansnomination committees sustainability committee committee andr hoffmann chair dr patrick frost chair andr hoffmann chair dr severin schwan chair prof dr akiko iwasaki dr jrg duschmal dr jrg duschmal andr hoffmann dr jemilah mahmood dr mark schneider anita hauser anita hauser dr claudia suessmuth dyckerhoff dr claudia suessmuth dyckerhoff prof dr richard p lifton bernard poussot contents letters shareholders sustainability report contribute corporate governance remuneration report corporate executive committee memberships corporate executive enlarged corporate executive committee committee enlarged corporate executive effective march dr levi garraway head committee changed follows global product development chief medical officer became new member enlarged corporate executive committee corporate executive committee election new chairman board directors roche holding ltd march april silke hrnstein former head dr severin schwan resigned member global strategy transformation roche corporate executive committee member since diagnostics became head corporate strategy ceo roche group since sustainability well secretary corporate executive committee new member effective march board directors enlarged corporate executive committee appointed dr thomas schinecker former ceo roche diagnostics dr schwans successor information member corporate ceo roche group due bill andersons executive committee enlarged corporate resignation ceo roche pharmaceuticals executive committee listed see effective december dr thomas schinecker also board directors became addition ad interim ceo roche corporate executive committee pharmaceuticals january february effective january matt sause former head roche diagnostics north america region succeeding dr thomas schinecker became ceo roche diagnostics member corporate executive committee effective march teresa graham former head global product strategy roche pharmaceuticals appointed ceo roche pharmaceuticals became member corporate executive committeecorporate governance roche corporate executive committee corporate executive committee ceo roche ceo roche ceo roche chief financial chief people group pharmaceuticals diagnostics information officer officer enlarged corporate executive enlarged corporate executive committee committee gred pred pharma partnering communications general counsel global product development corporate strategy sustainability contents letters shareholders sustainability report contribute corporate governance remuneration report corporate executive committee members nationality austria female us male germany switzerland years years years years years age tenure average tenure years incl dual citizen calculated first year membership corporate executive committee corporate governance roche composition name year birth nationality position since corporate executive committee dr thomas schinecker de ceo roche group member ceo teresa graham us ceo roche pharmaceuticals matt sause us ceo roche diagnostics dr alan hippe ch de chief financial information officer cristina wilbur us chief people officer enlarged corporate claudia bckstiegel ch de general counsel executive committee prof dr hans clevers nl head roche pharma research early development pred dr levi garraway us head global product development chief medical officer silke hrnstein de head corporate strategy sustainability dr aviv regev il us head genentech research early development gred dr james h sabry ca us global head pharma partnering barbara schdler de head group communications secretary corporate silke hrnstein de executive committee statutory auditors kpmg klynveld peat marwick goerdeler sa reporting years roche holding ltd kpmg ag since auditor charge john morris ian starkey mark baillache franois rouiller since chief compliance officer pascale schmidt members corporate executive committee cvs mandates detailed information available follows current members httpswwwrochecomaboutgovernanceexecutivecommittee b former members least ten years back httpswwwrochecomaboutgovernanceecbodformer c information reporting date december year least last ten years httpswwwrochecomaboutgovernancearchivformercvs information members corporate executive committee shown accordance directive information relating corporate governance dcg httpswwwseragcom damdownloadsregulationlistingdirectivesdcgenpdf also specifically includes mandates accordance article e article para point federal act amendment swiss civil code part five code obligations co may carried comparable positions undertakings commercial objects rules mandates applying members board directors corporate executive committee accordance articles incorporation roche holding ltd httpsassetscwprochecomfxbberochestatutenenpdf explained contents letters shareholders sustainability report contribute corporate governance remuneration report group structure shareholders roches operating businesses organised information roche holding ltd significant two divisions pharmaceuticals diagnostics subsidiaries associated companies including company name listing information domicile share pharmaceuticals division comprises capital equity interest listed finance two business segments roche pharmaceuticals report note roche group consolidated including genentech united states financial statements list subsidiaries chugai associates diagnostics division replaced major shareholders listed finance report previous business area structure four notes roche group consolidated business areas new customer areas sales financial statements equity attributable roche presented following customer areas core shareholders related parties pages lab molecular lab point care pathology lab note financial statements diabetes care details see finance report roche holding ltd significant shareholders addition significant shareholders published relevant webpage see link business activities carried group disclosure office six exchange subsidiaries associated companies detailed regulation roche pharmaceuticals incl genentech pharmaceuticals chugai core lab molecular lab diagnostics point care pathology lab diabetes care composition six exchange regulation httpswwwseragcomenresourcesnotificationsmarketparticipantssignificantshareholdershtmlcorporate governance roche andr hoffmann chairman corporate governance sustainability committee remuneration committee dr jrg duschmal member audit committee remuneration committee andr hoffmann vicechairman board directors chairman remuneration committee boards corporate governance sustainability committee member boards chairmansnomination committee dr jrg duschmal member board directors boards audit committee remuneration committee serve respective capacities board committees representatives shareholder group pooled voting rights receive remuneration set forth remuneration report finance report note roche group consolidated financial statements related parties relationships exist shareholders pooled voting rights crossshareholdings contents letters shareholders sustainability report contribute corporate governance remuneration report capital structure information roches capital structure provided information debt instruments finance report notes financial issued outstanding bonds provided statements roche holding ltd finance report note roche group additional details contained articles consolidated financial statements debt incorporation roche holding ltd information employee stock options provided movement recognised amounts last finance report note roche three financial years detailed finance group consolidated financial statements equity report notes financial statements compensation plans including detailed roche holding ltd information stocksettled stock appreciation rights ssars plan restricted stock units company share capital rsus plan roche connect roche chf divided fully option plan paid bearer shares nominal value chf restrictions exercise roche issued options apart employee voting rights bearer shares stock options described finance report note roche group consolidated authorised conditional capital financial statements equity compensation plans options issued connection addition nonvoting equity debt instruments securities nes issued bearer form form part share capital neither options awarded employees confer voting rights nes confers debt instruments issued rights one share participate available effect roches share capital earnings liquidation proceeds following repayment share capital roches nes rights pertaining thereto including provisions protecting interests nes holders described articles incorporation roche holding ltd httpswwwrochecomaboutgovernancearticleofincorporationcorporate governance roche board directors corporate executive committee information member board mandates shall mean mandates comparable directors member corporate functions companies economic executive committee listed pages purpose mandates different legal entities members board directors joint control beneficial ownership age limit restriction term office deemed single mandate curricula vitae cvs current former since annual general meeting elected members least last ten years members board directors chairman bodies information including information board directors members years first election board remuneration committee annual basis memberships additional positions memberships elections nominee voted activities available continuously separately see articles incorporation updated internet addition status roche holding ltd minutes cvs bodies relevant reporting th ordinary annual general meeting roche date december least last ten years holding ltd held march separately available exception dr severin schwan none rules pursuant article para point members board directors office federal act amendment swiss civil end member roches code part five code obligations co corporate executive committee served number permitted activities board executive capacity group subsidiary directors corporate executive committee three financial years preceding current members outlined articles reporting period lack existing incorporation roche holding ltd business connections group group member board directors may assume subsidiary independent roches board directors additional mandates independence definition based definition may publicly listed companies swiss code best practice corporate member corporate executive committee governance economiesuisse see httpswww may assume additional mandates economiesuissechsitesdefaultfilespublications may publicly swisscodeewebpdf complemented listed company specific preceding criteria see httpswwwroche restrictions apply comaboutgovernanceboardofdirectors mandates companies controlled company control principles governance principles b mandates member board delegation competence reservation powers directors corporate executive management group companies committee assumes order company executive bodies company include order companies controlled company economic environmental social topics c mandates associations foundations family principles together internal organisation foundations employee welfare foundations board directors division authority httpswwwrochecomaboutgovernanceboardofdirectors httpswwwrochecomaboutgovernanceexecutivecommittee addition see pages httpswwwrochecomaboutgovernancearticleofincorporation httpswwwrochecomaboutgovernanceannualgeneralmeetings contents letters shareholders sustainability report contribute corporate governance remuneration report board directors board directors board committees board committees chairmansnomination committee remuneration committee corporate governance sustainability committee audit committee corporate executive committee corporate executive committee ceo roche ceo roche ceo roche chief financial chief people group pharmaceuticals diagnostics information officer officer responsibilities board part management information system management remits board committees mis board access electronic information control mechanisms information platform provides timely available board dealings corporate information board directors management governed bylaws board committees system controls set forth board directors roche holding ltd organised ensure group conducts board directors established system businesses responsibly focus long controls continuously monitored term value creation end roche board audit committee corporate governance delegated certain responsibilities several sustainability committee board committees composition chairpersons directors consists following elements december described pages report operating financial risks risk committees authorities management system responsibilities defined detail bylaws roche group established risk board directors management process covering entire company system place identify manage committees exception types risks opportunities potentially chairmansnomination committee chaired affecting business including economic independent directors environmental social impacts board directors highest governance body involved according bylaws board directors roches risk management policy sets board meeting may convened without approach accompanying responsibilities chairman present request roches pharmaceuticals diagnostics divisions members roche board meets year group functions conduct formal assessment assess chairmans performance meeting process least year must develop attended chairman chaired management plans material risks vicechairman opportunities risk management httpswwwrochecomaboutgovernancearticleofincorporation httpswwwrochecomaboutgovernancecommittees httpswwwrochecomaboutgovernancearticleofincorporationcorporate governance roche plans monitored deviations reviewed developed together businessauditee regular performance dialogues consolidated tracked completion group risk report including target risk profile statutory auditors see discussed corporate executive committee chief compliance officer compliance officers approved together group business subsidiaries see plan board directors material risks safety security health environmental reviewed board yearly basis protection department effectiveness risk management process corporate sustainability steering committee monitored group risk advisory team scientific ethics advisory group seag overall process regularly reviewed external auditors findings presented members corporate executive committee audit committee full board details invited attend meetings board risk management risk management directors report person agenda policy see risk management website items concerning situation warrants financial risk management described members enlarged corporate executive finance report committee may also invited attend board system internal controls financial reporting committees invite chairman board see finance report corporate executive committee members deliver internal audit reports committee meetings may elect group audit reports administratively general commission independent expert reports call counsel direct access gives regular services consultants briefings audit committee corporate governance sustainability committee year several blackout periods imposed chairman board directors members board directors ongoing activities audit reports chief senior managers certain employees audit risk advisory executive attends audit prohibited trading company stock committee partly corporate governance following blackout periods arewere effect sustainability committee meetings respectively external auditors group audit independent appraisal function evaluates reviews blackout periods groups activities service board directors management annual audit december december plan yearly defined focus areas validated february february senior management approved audit april april april april committee roche group committed june july june july maintaining high standard internal control october october throughout worldwide operations management october october responsible assessing business risks aspects operation implementing effective efficient processes controls blackout periods changed chairman whilst ensuring compliance internal board directors circumstances warrant external rules regulations conducting operational audits group audit determines roche employees involved preparation managements response risks surrounding regular publicity events particular annual business processes systems evaluates halfyear reports media conferences quarterly appropriateness completeness efficiency sales releases otherwise access processes controls action plans potentially share price sensitive information implement necessary changes enhancements roche subject blackout periods httpswwwrochecomaboutsustainabilityapproachriskmanagement additional information provided finance report note roche group consolidated financial statements risk management httpswwwrochecomaboutsustainabilityenvironment httpswwwrochecomaboutsustainability httpswwwrochecominnovationethicalstandardsadvisory contents letters shareholders sustainability report contribute corporate governance remuneration report dr patrick frost chairman audit committee fullday meeting addition board went day trip major noneuropean affiliate board committees met follows chairmansnomination committee meetings approx hours remuneration committee meetings approx hours audit committee meetings approx hours irrespective whether relevant information share price sensitive roche corporate governance sustainability blackout periods persons shall keep committee meetings approx hours relevant information confidential must disclose noninsider within outside roche including family members ii buy sell board directors regularly conducts otherwise trade equity securities roche assessment selfassessment assessment shares nonvoting equity securities well third parties via electronic survey personal options similar instruments derivatives based interviews performance thirdparty thereon iii provide trading recommendations assessment took place thereon automatic execution predefined periodic purchase orders roche connect members corporate executive committee programme subject blackout maximum ordinary notice period twelve periods addressees scope exceptions months changeofcontrol clauses regard blackout periods please refer employment contracts roche group insider directive httpsassetscwp rochecomfxebgroupinsider management contracts policypdf reporting year exceptions fall within scope subsection annex general rules granted six directive information relating corporate governance board directors met meetings meetings hours length including remuneration committee members recuse deliberations decisions matters affect interests figures indicate actual length meetings include directors extensive premeeting preparations postmeeting followup activitiescorporate governance roche attendance board board committee meetings corporate governance chairmans nomination remuneration audit sustainability board committee committee committee committee number meetings schwan hoffmann j duschmal p frost hauser iwasaki member board since march r p lifton j mahmood b poussot schneider member board since march c suessmuth dyckerhoff c franz member board march member committee member since march member march guest contents letters shareholders sustainability report contribute corporate governance remuneration report remuneration shareholdings loans details regarding remuneration shareholdings rules aoi loans content method determining content board cec compensation shareholding programmes rules principles basic principles elements compensation applicable performance shareholding programmes serving former related pay members board directors corporate rules principles executive committee together description allocation equity securities authorities procedure determining convertible rights options set forth separate remuneration report additional amount pages finance report payments members notes roche group consolidated corporate executive financial statements equity attributable roche committee appointed shareholders related parties pages vote pay annual listed note financial general meeting statements roche holding ltd board shareholders executive shareholdings rules loans credit facilities postemployment benefits following rules remuneration shareholdings rules vote pay loans board directors board annual general meeting corporate executive committee cec set forth articles incorporation aoi httpswwwrochecomaboutgovernancearticleofincorporationcorporate governance roche participatory rights shareholders participatory rights shareholders articles incorporation defined roches articles incorporation shareholders alone together hold least roche shares issued bearer share capital votes may restrictions admission annual general later days annual general meetings exception shares must meeting request item included deposited within specified period agenda motion relating agenda item date meeting admittance card must included notice convening annual issued shareholders name provided general meeting articles incorporation shareholder elect represented third party rules issue instructions annual general meeting independent proxy rules electronic participation annual general meeting articles incorporation contain laid corresponding invitation restrictions exercise voting rights annual general meeting regulated quorum requirements stipulated articles incorporation conformity swiss code obligations co change control defensive measures articles incorporation contain provisions nonvoting equity securities would terminated mandatory bid rule swiss law applies event acquisition vesting period restrictions preexisting awards would changeofcontrol clauses removed options could components remuneration based roche exercised immediately httpswwwrochecomaboutgovernancearticleofincorporation contents letters shareholders sustainability report contribute corporate governance remuneration report relationship statutory auditors annual general meeting roche holding ltd services limits certain permitted march shareholders voted services agreed audit committee appoint kpmg ag kpmg statutory auditors potential nonaudit service engagement reviewed policy authority proceed based existing legal requirements swiss given code obligations article concerning maximum term office seven years auditor auditors direct access audit charge franois rouiller auditor committee chair well chief audit charge since business year information risk advisory executive discuss relevant issues long auditor charge serving capacity provided reports statutory auditor consolidated financial statements statutory auditors participate audit financial statements found pages committee meetings prepare written respectively finance report oral reports results audits audit committee oversees assesses auditors kpmg received following remuneration makes recommendations board services statutory auditors roche holding ltd information authorities responsibilities auditors roche companies audit committee see article bylaws including chugai statutory auditors participated five meetings audit committee millions chf performance kpmg assessed based audit services different elements affiliate surveys auditrelated services evaluate service level country level assurance interviews roche key stakeholders tax services selfevaluation kpmg internal processes services ensure compliance federal audit oversight total authority faoa audit committee guide kpmgs independence ensured limiting audit fee reviewed chief audit risk kpmg providing certain nonaudit services advisory executive approved audit furthermore permitted services exceed committee every year takes consideration total audit fee unless explicitly changes roches business well changes rewieved approved audit committee financial reporting audit standards company formal policy governing regulations engagement statutory auditor nonaudit httpswwwrochecomaboutgovernancearticleofincorporationcorporate governance roche statutory auditors elected year services include advice relating process annual general meeting improvements regulations trainings audit services provided legally required external audit services tender completed external auditing services starting auditrelated services include assurance financial year four audit firms accounting services provided auditors invited participate conluded based necessarily provided statutory assessment audit firms part tender auditor services go beyond legal process reappoint kpmg external auditor requirements could include attestation financial year services comfort letters consultations tax services include services respect compliance tax returns tax advice except services related audit tax relationship independent proxy since testaris ag served general meeting period independent proxy annual general conclusion ordinary annual meeting march shareholders elected general meeting shareholders testaris ag independent proxy period conclusion rules issue instructions ordinary annual general meeting shareholders independent proxy rules electronic testaris ag paid services annual participation annual general meeting general meeting according expenditure laid corresponding invitation totalling chf chf annual general meeting regulated articles incorporation board directors nominates testaris ag election independent proxy annual contents letters shareholders sustainability report contribute corporate governance remuneration report information policy provided articles incorporation presentations analyst investor conferences corporate notices published swiss available internet publications official gazette commerce daily available newspapers designated board directors httpswwwrochecompublications basler zeitung finanz und wirtschaft lagefi ordered le temps neue zrcher zeitung email materialsmanagementmmrochecom fax roche reports halfyear fullyear results business reports published print andor online contact address investor relations formats media events addition detailed f hoffmannla roche ltd investor relations firstquarter ninemonth sales figures group finance basel switzerland published year april october tel current list publication dates available fax internet additional information including details specific relevant information documents including contact persons available internet media releases investor updates chief compliance officer compliance officers network chief compliance officer compliance supervisors local compliance officer officers network committed ensuring report chief compliance officer roche group code conduct consistently ms pascale schmidt email complied throughout roche group globalcomplianceadministrationrochecom chief compliance officer also serves contact disclosures treated confidentially person shareholders employees business addition employees third parties may partners customers suppliers general anonymously report irregularities complaints public issues relating implementation mother tongue via roche group speakup compliance code line part continuous enhancement roches human rights programme compliance employees parties become aware applicable laws regulations interested violations roche group code conduct party report allegations bring attention managers channel believe good faith actual httpswwwrochecomaboutgovernancearticleofincorporation httpswwwrochecommedia httpswwwrochecominvestors httpswwwrochecomcontactinvestorcontacts httpswwwrochecomaboutgovernancecodeofconduct httpswwwrochecomaboutgovernancecodeofconductcomplianceofficercorporate governance roche potential human right violation occurred business ethics incidents recorded roche roches value chain case questions system internal investigations team uncertainties interpretation regionallocal management receives specific roche group code conduct reference concrete information alleged violation documents employees may reach roche group code conduct one line managers local compliance officer certain predefined categories corporate chief compliance officer contact governance sustainability committee roche group code conduct help advice audit committee board directors line globalhelpandadvicerochecom regularly informed substantial violations compliance tool also serves platform ideas managements corrective actions taken suggestions concerning documents chief compliance officer reports addition roche established business ethics general counsel also submits regular reports incident management system beims enables corporate governance sustainability chief compliance officer capture track committee needed audit committee monitor alleged violations initial reports board directors resolution nonapplicabilitynegative disclosure expressly noted information six swiss exchange directive information contained mentioned herein either relating corporate governance nonapplicable omission construed commentary thereto negative declaration provided httpswwwrochecomaboutgovernancecodeofconduct contents letters shareholders sustainability report contribute corporate governance remuneration reportremuneration report roche remuneration report principles remuneration decision process approval framework remuneration components remuneration board directors remuneration corporate executive committee statutory auditors report contents letters shareholders sustainability report contribute corporate governance remuneration report principles overview global company like roche market motivation expertise performance competitive remuneration plays key role employees key success roche along performance successbased innovative agile company conviction transparent compensation structure ensure forms basis compensation policy compensation packages competitive structure individual components roche aims remunerate employees fairly regularly benchmarked based relevant transparently line market conditions swiss european international market criteria order enable participate appropriately remuneration guidelines underlying companys success pursue goal principles also subject regular outside providing equitable competitive performance comparisons based resultsoriented compensation however compensation policy one strive balanced mix fixed variable factor safeguarding roches future success compensation components geared key element corporate culture offers employees position management responsibility employees conditions make best possible contribution shared corporate firstly variable components intended goal improving healthcare patients create additional financial incentives achieve includes sound sustainabilityoriented corporate goals keep innovation value system based integrity courage consistently high level increasing value passion time decentralised company creates stakeholder management approach plays major role groups secondly order allow employees wide scope individual decisionmaking managers participate companys business respectful interactions openness diversity wide success variable compensation components ranging training development opportunities key objectives incentivised annual attractive working environment bonus payments longterm securitiesbased unidimensional diminishment questions programmes remuneration would fall far short roche place work httpscareersrochecomglobalen members board directors corporate executive committee cvs mandates detailed information available follows board directors corporate executive committee current members httpswwwrochecomabout httpswwwrochecomabout governanceboardofdirectors governanceexecutivecommittee b former members httpswwwrochecomaboutgovernanceecbodformer least last ten years c information reporting date december year httpswwwrochecomaboutgovernancearchivformercvs least last ten years audited information activities companies accordance art e co found link c information members board code obligations co may carried directors corporate executive comparable positions undertakings committee shown accordance commercial objects directive information relating corporate governance dcg httpswwwseragcomdam rules mandates applying members board downloadsregulationlistingdirectivesdcgen directors corporate executive committee pdf also specifically includes mandates accordance articles accordance article e article incorporation roche holding ltd httpsassetscwp para point federal act rochecomfxbberochestatuten amendment swiss civil code part five enpdf addition see detidua remuneration report roche contents letters shareholders sustainability report contribute corporate governance remuneration report remuneration decision process approval framework overview present remuneration committee year remuneration committee roches decides corresponding compensation board directors decides remuneration right say decisions decision board members members groups right reserved remuneration committee corporate executive committee members chairman group ceo members groups corporate executive committee must remuneration decision process approval framework beneficiary remuneration board directors bod corporate executive decision approval components chairman c committee cec base pay basic remuneration bonus stocksettled stock remuneration committee annual general meeting appreciation rights ssars restricted stock units rsus pension c remuneration committee tracks market data total aggregate amounts based salaries leading global pharmaceutical decisions submitted general meeting companies major swiss companies approval general meeting shall vote reports findings full board external annually binding effect approval consulting firm pricewaterhousecoopers ag pwc remuneration board directors assists remuneration committee roche resolved board directors performing market comparisons corporate executive committee details see advisor pwc additional mandates roche group information remuneration committees remit powers procedures making remuneration decisions found bylaws roche board directors articles incorporation also outlined sections principles governing specific remuneration components see peer set abbott laboratories abbvie amgen astrazeneca bristolmyers squibb danaher eli lilly glaxosmithkline johnson johnson medtronic merck co novartis novo nordisk pfizer sanofi peer set abb alcon holcim lonza nestl richemont ubs zurich httpswwwrochecomaboutgovernancearticleofincorporation httpswwwrochecomaboutgovernancearticleofincorporationremuneration report roche abbott laboratories peer set abbvie amgen abb astrazeneca alcon bristolmyers squibb holcim danaher lonza eli lilly nestl glaxosmithkline richemont johnson johnson roche ubs medtronic zurich merck co novartis novo nordisk pfizer sanofi peer set market comparison companies salary assessment pharma peer set major swiss companies contents letters shareholders sustainability report contribute corporate governance remuneration report andr hoffmann chairman remuneration committee procedure submitting total board retrospective approval executive remuneration shareholder total aggregate bonus amounts corporate approval annual general meeting executive committee chairman year annual general meeting agm board directors resigned shareholders approve total remuneration chairman financial year ended board directors corporate submitted retrospectively ordinary agm executive committee decided board separate binding approval directors remuneration committee board directors respectively prospective approval board executive aggregate according approval agm remuneration submitted prospectively roche committed obtaining separate agm separate binding approval binding shareholder approvals total period two ordinary agms remuneration paid board directors corporate executive committee remuneration report shall submitted follows advisory vote shareholders agm remuneration report roche approval total remuneration annual general meeting agm financial year financial year approval total remuneration retrospective c chairman c board directors bod bonus bonus financial year total amount resigned c cec corporate executive committee cec bonus bonus financial year total amount prospective bod board directors bod basic remuneration aggregate total remuneration agm agm basic remuneration cec corporate executive committee cec base pay aggregate total remuneration agm agm ssars base pay rsus stocksettled stock appreciation rights ssars indirect benefits restricted stock units rsus indirect benefits advisory vote retrospective remuneration report advisory vote remuneration report agm agm agm agm contents letters shareholders sustainability report contribute corporate governance remuneration report remuneration components overview remuneration elements financial performance nonfinancial success remuneration members board thus align interests roche directors corporate executive committee employees shareholders societal composed following elements environmental objectives also taken account corporate executive committees fixed base salary complemented annual variable lti remuneration components intended bonus shortterm incentive sti sustainably homogenously longterm perennial remuneration elements ssars rsus oriented perspective align managements interest longterm incentive lti shareholders holders non voting equity securities give participating remuneration components linked managers additional incentive achieve employees performance companys sustainable shareholder value growth composition remuneration board directors corporate executive committee board directors corporate executive committee annual remuneration elements c bod ceo roche group cec base pay basic remuneration cash ten years cash cash cash see blocked nonvoting equity securities andor shares bonus cash nonvoting equity cash see securities andor shares pensions etc see perennial remuneration elements stocksettled stock appreciation rights ssars see restricted stock units rsus see httpswwwrochecominvestorsreportsperformance httpswwwrochecomaboutsustainabilityenvironmentgoalsperformanceremuneration report roche lti corporate executive committee expiration periods aligned newly issued enlarged corporate executive ssars rsus see unlike committee composed ssars participants two programmes members rsus based already existing individual corporate executive committee choice target value total lti corporate executive determining mix rsus ssars committee members base pay since fouryear cliff vesting measured january year vesting corporate executive committee lti mix ssarsrsus fixed base calculation vesting period cliff vesting expiration period based individual target ssars years years years value total lti corporate executive committee members base pay measured rsus years years january year remaining participants ssars offering level choice empowers participants rsus programme offered yearly basis engage fully total rewards enables choice three combinations determine mix better understand critical element restricted stock units rsus stocksettled compensation increases value stock appreciation rights ssars options used programme instead ssars countries following options available attractively designed roche longterm incentive programme enables roche attract choice choice choice motivate retain best talent keep ssars ssars ssars aligned companys longterm success rsus rsus rsus contents letters shareholders sustainability report contribute corporate governance remuneration report fixed base pay basic remuneration indirect benefits employer contribution roche pensions insurance contributions remuneration roche connect sti tax consulting services components bonus expense allowances lti stocksettled stock appreciation rights others restricted stock units childrens schooling costs foreign tax obligation variable longterm ahvivalv employer contribution social securities beneficial parts base pay fixed bonuses variable base pay basic remuneration determined bonuses annually awarded individual position based salary market data contributions value creation business year leading global pharmaceutical companies see meant incentive strive outstanding footnote major swiss companies results create new business opportunities see footnote reflects individuals abilities bonus amounts linked group divisional experience performance time pay core profits sales growth constant exchange adjustments likewise linked individual rates operating profit capital charge opac performance take account prevailing based core operating profit core earnings per market conditions companys overall share nonvoting equity security nes growth financial situation constant exchange rates product development pipeline diversity employees managers remuneration committee makes reviews environmental goals additionally linked final decision basic remuneration paid achievement measurable qualitative chairman board directors individual functional performance objectives individual base pay members corporate competitive reasons roche disclose executive committee remuneration individual performance objectives members members board corporate executive committee chairman httpswwwrochecomaboutpeopleculture httpswwwrochecomaboutsustainabilityenvironmentgoalsperformance goals roche group httpsassetscwprochecomfxfshegoalscommunicationpdfremuneration report roche december end reporting year restricted stock units rsus longterm january following reporting year proportion restricted stock units rsus remuneration committee decides bonuses members corporate executive committee amounts payable members total lti based individual corporate executive committee target value total lti corporate executive chairman board committee members base pay resigned chairman respect relevant measured january year reporting year based performance aforementioned objectives time rsus contain rights receive nonvoting equity remuneration committee also decides securities andor shares fouryear vesting form bonuses awarded ie cash payments period plus value adjustment amount andor blocked applicable nonvoting equity equivalent sum dividend paid securities andor shares vesting period attributable number nonvoting equity securities andor shares remuneration committee uses discretion individual award granted appropriately weighting criterion vested recipient corporate bonus allocation executive committee four years thereafter resulting nonvoting equity securities total employees eligible andor shares may remain blocked bonus roche bonus program ten years stocksettled stock appreciation rights rsu awards allocated individually ssars longterm corporate executive committee ssars proportion lti corporate remuneration committees discretion executive committee based individual target value total lti corporate rsus served remuneration component executive committee members eligible roche employees base pay measured january year indirect benefits ssars entitle holders benefit financially shown ceo roche group increase value roches nonvoting chairman respectively members equity securities grant date corporate executive committee additionally exercise date ssars granted vest together received indirect benefits pension funds insurance four years exercised contributions roche connect payments foreign within ten years grant date unexercised tax obligation tax consulting services ssars lapse without compensation fair value annual expense allowances individual members ssars calculated grant date using corporate executive committee received trinomial model american call options payments shown details see ssars corporate executive committee allocated individually remuneration committees discretion total employees received ssars contents letters shareholders sustainability report contribute corporate governance remuneration report weighting fixed variable longterm remuneration components target percentage total remuneration board directors including chairman corporate executive committee including ceo roche group fixed variable longterm variable longterm remuneration paid members corporate executive committee ranged total compensation ratio variable remuneration components relative fixed base pay corporate executive committee ratio variable remuneration components bonuses ssars rsus relative value fixed base pay lti longterm sti variable total criteria bonus ssars total lti rsus total lti individual target value minimum maximum performance criteria group objectives group divisional business value development value development performance individual objectives considering determined determined core profits sales growth constant exchange rates performance performance plus operating profit capital charge opac based nes grant value adjustment core operating profit core earnings per share dividends nonvoting equity security nes growth constant nes grant exchange rates product development pipeline diversity employees managers environmental goals split group objectives na na b individual objectives na na weighting criteria remuneration committees discretion decision objectives na applicable assessed consideration performance competitors macroeconomic development based already existing individual target value total lti corporate executive committee members base pay measured january year details please refer following sections remuneration report see also finance report note roche group consolidated financial statements related parties note financial statements roche holding ltd board executive shareholdings remuneration board directors resolution approval amount remuneration members remuneration chairman board board directors directors members board directors members board directors decided remuneration committees received remuneration additional compensation discretion shown remuneration members board directors table remuneration form cash payments board activities roche paid employer contributions annually tracked market data totalling chf chf social directors pay leading global security agencies members board pharmaceutical companies see footnote directors beside legally required contributions major swiss companies see footnote separately stated incumbent assisted consultancy pwc resigned chairman board directors previous years board directors basic remuneration board directors submit total aggregate bonus resigned excluding chairman remained unchanged chairman board directors since financial year general meeting retrospective binding approval exception resigned chairman board directors bonus form blocked new incumbent chairman board shares incumbent chairman board directors base remuneration directors award blocked shares part determined remuneration committee basic remuneration members board consist cash component new component directors awarded shares nonvoting form shares blocked ten years equity securities ssars rsus time bonus component longer apply incumbent chairman board loans credits granted directors members board directors maximum amount total aggregate advisory service genentech remuneration board directors scientific resource board prof dr akiko iwasaki period ordinary general meeting prof dr richard p lifton received honoraria ordinary general meeting amounting usd chf tabled separately previous years usd chf respectively general meetings prospective binding approval see list members positions committee memberships chairmanships see detidua remuneration report roche detidua contents letters shareholders sustainability report contribute corporate governance remuneration report remuneration members board directors chf additional remuneration additional special additional basic remuneration committee memberschairs remuneration bvg costs total remuneration schwan chairman see total remuneration paid incumbent resigned chairman board directors hoffmann vicechairman j duschmal p frost hauser iwasaki since march see r p lifton see j mahmood b poussot schneider since march c suessmuth dyckerhoff total resigned member c franz april see total remuneration paid incumbent resigned chairman board directors costs provisions swiss federal occupational old age survivors invalidity pension act bvg accordance minimum requirements insurance benefits bvg half costs four members board directors subject compulsory insurance borne company exception members chairmans committee chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board p rorated remuneration period march december additionally employer contribution ahvivalv totalling chf including chairman paid form part remunerationremuneration members board directors chf additional remuneration additional special additional basic remuneration committee memberschairs remuneration bvg costs total remuneration c franz chairman see annual report total remuneration paid chairman board directors hoffmann vicechairman j duschmal p frost hauser r p lifton j mahmood since march b poussot schwan see annual report highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee c suessmuth dyckerhoff members march september p bulcke march h clevers march j brown september total costs provisions swiss federal occupational old age survivors invalidity pension act bvg accordance minimum requirements insurance benefits bvg half costs four members board directors subject compulsory insurance borne company w ith exception members chairmans committee chairman vicechairman board members receive chf year committee serve chf year committee chair r emuneration serving vicechairman board p rorated remuneration period march december prorated remuneration period january march january september respectively dditionally employer contribution ahvivalv totalling chf including chairman paid form part remuneration detidua remuneration report roche total remuneration paid incumbent since election march dr severin schwan resigned chairman board incumbent chairman received total remuneration directors shown resigned chairman dr christoph franz received total remuneration listed resignation april detidua total remuneration paid incumbent chairman board directors dr severin schwan chf base salary na cash dr severin schwan shares executive member pension funds insurances annual expense allowances children education board directors received allowance including employer contribution social securities beneficial parts remuneration total primary function ceo roche group na applicable remuneration since april chairman board directors remuneration resigned ceo january march see respectively form shares blocked ten years calculation number shares based price date transfer calculation value consideration reduction value due blocking period ten years reduced market value additionally employer contribution ahvivalv chf paid form part remuneration detidua contents letters shareholders sustainability report contribute corporate governance remuneration report total remuneration paid resigned chairman board directors dr christoph franz chf base salary cash bonus subject approval annual general meeting pension funds insurances annual expense allowances remuneration including employer contribution social securities beneficial parts total remuneration april chairman board directors per terms resignation agreement dr christoph franz remained roche end april ensure smooth handover successor received remuneration april form shares blocked ten years calculation number shares based price date transfer march respectively approval agm agm respectively calculation value consideration reduction value due blocking period ten years reduced market value submitted shareholder approval agm approved agm respectively including fee dr christoph franz amounting total jpy million chf received serving member board directors chugai pharmaceutical co ltd additionally employer contribution ahvivalv chf chf paid form part remuneration remuneration committees bonus proposal total remunerations contained total resigned chairman respect remuneration board directors financial year form shares blocked ten years payable march put shareholder binding vote ordinary annual general meeting see total remuneration paid board submission boards total aggregate directors future remuneration period calendar year members ordinary agm ordinary board directors including incumbent agm prospective binding shareholder resigned chairman board vote agm directors received remuneration including board directors proposes bonus resigned chairman employer ordinary agm approve board remuneration totalling contribution social securities beneficial parts chf excluding legally totalling chf chf required employer contributions ahvivalv excluding additional employer contribution period ordinary agm paid social securities totalling chf ordinary agm compensation chf members board directors paid cash chairman board directors remuneration paid former members compensation consists component cash board directors component form shares blocked remuneration paid ten years calculation value consideration reduction value due blocking period board remuneration subject approval ten years reduced market value annual general meeting determined remuneration committee submission resigned chairmans reconciliation reported total aggregate bonus binding remuneration shareholders retrospective vote annual general prospectively approved remuneration meeting members board directors remuneration resigned chairman ordinary agm prospectively approved board directors includes bonus award board remuneration totalling chf form shares blocked chf excluding legally required ten years shown table section total employer contributions ahvivalv excluding remuneration paid incumbent bonuses period ending ordinary resigned chairman board directors agm comparison ordinary agm board directors submit remuneration ordinary agm actual remuneration committees bonus proposal resigned amounted chf excluding legally chairman respect financial year required employer contributions ahvivalv form shares blocked ten years payable excluding bonuses remained within march excluding legally required employer approved total remuneration limit contributions ahvivalv retrospective binding shareholder vote ordinary annual general meeting agm detidua remuneration report roche ordinary agm approved board remuneration security holdings totalling chf excluding directors andr hoffmann dr jrg duschmal legally required employer contributions members founders families ahvivalv excluding bonuses period closely associated belong ending ordinary agm contractually bound shareholder group pooled voting rights end change chairman board group held shares issued directors remuneration components shares detailed information group changed insofar one found finance report note hand longer bonus remuneration roche group consolidated financial statements chairman board directors related parties note hand base compensation increases financial statements roche holding ltd consists component cash significant shareholders component form shares blocked ten years calculation value consideration addition december reduction value due blocking period december respectively members ten years reduced market value per board directors persons closely remuneration committees decision see associated held roche shares non ordinary agm ordinary voting equity securities nes american agm actual remuneration excluding legally required depositary receipts adrs shown table employer contributions ahvivalv including security holdings shares nes adrs reduction blocking period remained within approved total remuneration limit detailed calculation made reported end aforementioned period security holdings shares nes adrs december december nonvoting close nonvoting close equity relatives equity relatives securities others security securities others security shares nes number holdings shares nes number holdings number number type numbertype number number type numbertype board directors schwan hoffmann j duschmal p frost hauser nes nes iwasaki na na na na r p lifton adrs adrs j mahmood b poussot schneider na na na na c suessmuth dyckerhoff total adrs nes adrs nes na applicable shares held shareholder group pooled voting rights listed jointly held close relative r oches adr american depositary receipt listed otcqx httpswwwotcmarketscomstockrhhbyquote international premier symbol rhhby isin us traded usd eight adrs represent one underlying nes detidua contents letters shareholders sustainability report contribute corporate governance remuneration reportas chairman dr severin schwan entitled receive new ltis ssars rsus ltis awarded former role ceo listed detidua detidua remuneration report roche tables stocksettled stock appreciation rights ssars restricted stock units rsus stocksettled stock appreciation rights ssars number ssars held december schwan awarded former role ceo price chf market price per nes december chf expiry date grant value per ssar chf since trinomial model american call options restricted stock units rsus number rsus held december schwan awarded former role ceo grant value per rsu chf chf chf chf nes closing price nes closing price nes closing price nes closing price grant date grant date grant date grant date march march march march contents letters shareholders sustainability report contribute corporate governance remuneration report remuneration corporate executive committee resolution approval remuneration remuneration committee remuneration members corporate board directors outlined executive committee decided remuneration decision process remuneration committees discretion taking approval framework account market comparisons members corporate executive previous years board committee received remuneration work directors separately submit total aggregate shown amount remuneration bonuses corporate executive committee ceo roche group dr thomas schinecker financial year general meeting explained detail total remuneration retrospective binding approval corporate executive committee shown maximum amounts total aggregate remuneration corporate executive remuneration dr severin schwan committee period ordinary role resigned ceo roche group reflected general meeting ordinary general remuneration components see meeting tabled separately included aggregated total remuneration previous years general meetings corporate executive committee see prospective binding approval see amount remuneration members corporate executive committee general provisions assigning authority decisions corporate executive committee base pay members corporate executive committee detidua detidua remuneration report roche highest total remuneration paid remuneration paid member corporate dr thomas schinecker member executive committee reflected following corporate executive committee chart included total amount paid ceo roche group including ad interim ceo corporate executive committee see total roche pharmaceuticals januarymarch remuneration paid members corporate dr thomas schinecker received highest executive committee highest total remuneration paid dr thomas schinecker incumbent ceo roche group member corporate executive committee chf base salary na bonus subject approval total aggregate bonuses corporate executive dr thomas committee annual general meeting schinecker received ssars remuneration role rsus ceo roche diagnostics roche connect pension funds insurances payments incl expense allowance tax consulting services total na applicable including employer contribution social securities beneficial parts form shares calculation number shares based price date transfer march approval agm sars number grant value according trinomial model american call options chf trinomial model american call options value described stocksettled stock appreciation rights ssars members corporate executive committee ssars blocked four years may thereafter exercised whilst nonvoting equity securities resulting exercise automatically blocked additional four years calculation value nonvoting equity securities consideration reduction value due additional blocking period four years reduced market value c alculation rsus value number rsus multiplied grant value chf nes closing price grant date march per rsu calculation value nonvoting equity securitiesshares consideration reduction value due blocking period ten years reduced market value includes annual expense allowance chf payments tax consulting services chf family children education allowance chf additionally employer contribution ahvivalv chf paid form part remuneration base pay chf graham na hippe sause na c wilbur total na applicable role ceo roche group dr severin schwan received chf base salary bonuses members receive bonus cash payment corporate executive committee dr thomas schinecker receive bonus remuneration committee board form roche shares bonus payment due directors determined corporate executive march committee members bonuses based performance agreed objectives role ceo roche group remuneration committee uses discretion dr severin schwan receive bonus award appropriately weighting criterion chf form roche shares bonus allocation total aggregate amount blocked ten years bonus part bonuses brought forward binding total aggregate amount bonuses vote annual general meeting corporate executive committee brought forward binding vote annual except dr thomas schinecker members general meeting corporate executive committee bonus chf subject approval total aggregate bonuses corporate executive committee annual general meeting graham na hippe sause na c wilbur total na applicable detidua contents letters shareholders sustainability report contribute corporate governance remuneration report stocksettled stock appreciation rights securities nes grant date ssars members exercise date strike price ssars corporate executive committee terms multiyear plan closing ssars members corporate price roche nes grant date ssars executive committee allocated individually since vest four previously granted ssars remuneration committees discretion three years grant date vested ssars ssars shown stocksettled stock exercised converted nes within ten appreciation rights ssars table previously granted ssars within seven years entitle holders benefit financially grant date unexercised ssars lapse increase value roches nonvoting equity without compensation shares blocked ten years calculation number shares based share price date transfer march approval agm calculation shares consideration reduction value due blocking period ten years reduced market value information trinomial model american call options please refer boyle phelim p lattice framework option pricing two state variables journal financial quantitative analysis volume issue mar httpsassetscwprochecomfxefdetrinomialmodelpdf ssars see number grant value according trinomial model american call options chf ssars blocked four years may thereafter exercised whilst nonvoting equity securities resulting exercise automatically blocked additional four years calculation value nonvoting equity securities consideration reduction value due additional blocking period four years reduced market value detidua remuneration report roche since ssars proportion lti compared european option corporate executive committee based allows exercise maturity date already existing individual target value total lti corporate executive committee numbers ssars strike prices expiry members base pay measured dates grant values ssars shown january year stocksettled stock appreciation rights ssars table numbers fair value ssars calculated ssars calculated time issue grant date using trinomial model american entered values tables call options trinomial model effective role ceo roche method valuation american call options group dr severin schwan received ssars totalling considers possibility exercising option chf time prior maturity called american option stocksettled stock appreciation rights ssars grant value per grant value per number ssar chf value chf number ssar chf value chf graham na na na hippe sause na na na c wilbur total price chf expiry date price chf expiry date na applicable restricted stock units rsus newly defined fouryear vesting period plus members corporate value adjustment amount equivalent executive committee sum dividend paid vesting since proportion restricted stock units period attributable number nonvoting rsus members corporate executive equity securities andor shares committee total lti based individual award granted already existing individual target value total vested recipient corporate executive lti corporate executive committee members committee four years thereafter base pay measured january resulting nonvoting equity securities andor year rsu awards allocated individually shares may remain blocked ten years corporate executive committee role ceo roche group dr severin remuneration committees discretion schwan received rsus totalling chf rsus contain rights receive nonvoting equity securities andor shares since detidua contents letters shareholders sustainability report contribute corporate governance remuneration report restricted stock units rsus value grant value grant number chf value chf number chf value chf graham na na na hippe sause na na na c wilbur total na applicable calculation value consideration reduction value due additional blocking period ten years reduced market value c alculation rsus value see number rsus multiplied grant value chf nes closing price grant date march per rsu calculation value nonvoting equity securities shares consideration reduction value due blocking period ten years reduced market value indirect benefits members subject holding period four years corporate executive committee switzerland employer contributions made social security schemes pension plans groupwide addition members corporate executive employee stock purchase plan roche connect committee received annual expense allowances respect members corporate executive members payments foreign tax committee shown indirect benefits obligations tax consulting services shown employer contributions table table payments employer contributions table indirect benefits payments pension funds insurances expense allowance family children roche connect voluntary stock purchase plan education allowances roche connect tax offering employees opportunity buy roche consulting fees including employer contribution nonvoting equity securities nes amount social securities beneficial parts equal annual base salary dr severin schwan amounted chf discount nes purchased plan detidua detidua indirect benefits employer contributions chf payments payments annual tax tax pension annual tax tax pension funds expense roche consulting funds expense roche consulting insurances allowances connect services insurances allowances connect services graham na na na na hippe sause na na na na c wilbur total na applicable including employer contribution social securities beneficial parts detidua remuneration report roche remuneration loans members company granted loans credits corporate executive committee members corporate executive committee meet contractual obligations roche paid total chf relocation costs maximum regular period notice members corporate executive committee months additional payments included changeofcontrol clauses total remuneration members corporate employment contracts executive committee remuneration former members board directors proposes awarding corporate executive committee members corporate executive committee meet legal contractual obligations bonuses dr severin schwan resigned ceo roche paid remuneration chf form roche shares blocked excluding legally required employer contributions ten years dr thomas schinecker incumbent ahvivalv chf bill anderson ceo roche group form shares resigned corporate executive members corporate executive committee end december committee cash payment see totalling chf respect payments former members financial year chf excluding corporate executive committee made legally required employer contributions social security agencies submit proposed total total remuneration paid members amount ordinary annual general meeting agm corporate executive committee retrospective approval vote calendar year members corporate executive committee including submission corporate executive dr severin schwan resigned ceo received committees total future aggregate remuneration including bonuses employer remuneration period contribution social securities beneficial parts ordinary agm ordinary agm totalling chf chf prospective binding shareholder approval excluding additional employer contribution annual general meeting paid ahvivalv totalling chf board directors proposes chf form part ordinary agm approve remuneration remuneration corporate executive committee totalling chf excluding legally additional remuneration required employer contributions ahvivalv abovementioned payments paid current excluding bonuses period former members corporate executive ordinary agm ordinary agm committee amount corporate executive corporate executive committees committees total future aggregate remuneration remuneration subject approval composed base pay longterm incentives ssars annual general meeting calculated grant value rsus see calculated time reservation nonvoting submission corporate executive equity securities shares pension benefits committees total aggregate bonuses excluding legally required employer contributions respect financial year ahvivalv well contributions retrospective binding approval annual expenses payments foreign tax obligations general meeting tax consulting services roche connect detidua contents letters shareholders sustainability report contribute corporate governance remuneration reportremuneration report roche reconciliation reported option partially reclaim distributed compensation remuneration shareholders result special circumstances clawback prospectively approved remuneration members corporate executive employee voluntarily serves notice committee termination employment ssars see ordinary agm approved remuneration rsus see unvested date corporate executive committee totalling termination employment lapse immediately chf excluding legally without compensation required employer contributions ahvivalv excluding bonuses period ending upon termination employment result ordinary agm comparison serious misconduct ssars rsus granted ordinary agm ordinary agm outstanding whether vested unvested actual remuneration amounted chf shall lapse immediately without compensation excluding legally required employer contributions according ssars plan rules serious ahvivalv excluding bonuses total misconduct participant may include remained within approved total amount inter alia activity leading serious disciplinary action detailed calculation actual repeated willful failure perform duties remuneration comparison remuneration reasonably assigned roche corporate executive committee approved violation law public regulation ordinary agm totalling commission crime chf excluding legally required gross negligence willful misconduct employer contributions ahvivalv excluding employment bonuses period ending ordinary engaging conduct bringing disgrace agm made reported end disrepute roche andor subsidiaries aforementioned period violation roches directives guidelines relating business conduct clawback addition applicable statutory provisions roches longterm incentive plans include guidelines security holdings five years march case since members corporate executive new members within five years start committee required hold roche securities employment members corporate executive committee requirement roche security holdings required hold roche securities equivalent ceo roche group remains unchanged value respective annual base annual base salary without fiveyear salary requirement must fulfilled within limitation new type security value acquired ceo roche group shares andor nes annual base salary members corporate executive committee shares andor nes annual base salary security holdings associated held securities shown december december following tables shares nonvoting equity respectively members corporate securities nes stocksettled stock appreciation executive committee persons closely rights ssars restricted stock units rsus shares nonvoting equity securities nes december december shares nes close relatives security holdings shares nes close relatives security holdings number number numbertype number number numbertype corporate executive committee shares nes shares nes schinecker graham na na na na hippe sause na na na na c wilbur total na applicable detidua contents letters shareholders sustainability report contribute corporate governance remuneration report stocksettled stock appreciation rights ssars number ssars held december corporate executive committee schinecker graham hippe sause c wilbur total price chf market price per nes december chf expiry date grant value per ssar chf since trinomial model american call options restricted stock units rsus number rsus held december corporate executive committee schinecker graham hippe sause c wilbur total grant value per rsu chf chf chf chf nes closing price nes closing price nes closing price chf grant date grant date grant date nes closing price march march march grant date march april respectively detidua detidua remuneration report roche general meeting roche holding ltd basel report audit remuneration report opinion opinion remuneration report audited remuneration report cover information express roche holding ltd company year form assurance conclusion thereon ended december audit limited information pursuant art af connection audit remuneration swiss code obligations co sections report responsibility read marked grey line audited including information consider whether respective footnotes pages information materially inconsistent remuneration report audited financial information remuneration report knowledge opinion information pursuant obtained audit otherwise appears art af co accompanying materially misstated remuneration report complies swiss law companys articles incorporation based work performed conclude material misstatement basis opinion information required report conducted audit accordance swiss fact nothing report regard law swiss standards auditing sach responsibilities provisions board directors responsibilities standards described auditors remuneration report responsibilities audit remuneration board directors responsible report section report independent preparation remuneration report company accordance provisions accordance provisions swiss law swiss law requirements swiss companys articles incorporation audit profession fulfilled internal control board directors ethical responsibilities accordance determines necessary enable preparation requirements remuneration report free material misstatement whether due fraud error believe audit evidence board directors also responsible obtained sufficient appropriate provide designing remuneration system defining basis opinion individual remuneration packages information auditors responsibilities audit board directors responsible remuneration report information information comprises objectives obtain reasonable information included annual report assurance whether information pursuant include sections marked audited art af co free material remuneration report consolidated financial misstatement whether due fraud error statements standalone financial statements issue auditors report includes auditors reports thereon opinion reasonable assurance high level ofstatutory auditors report roche assurance guarantee audit btain understanding internal control conducted accordance swiss law relevant audit order design audit sach always detect material misstatement procedures appropriate exists misstatements arise circumstances purpose fraud error considered material expressing opinion effectiveness individually aggregate could companys internal control reasonably expected influence economic e valuate appropriateness accounting decisions users taken basis policies used reasonableness remuneration report accounting estimates related disclosures made part audit accordance swiss law sach exercise professional judgement communicate board directors maintain professional skepticism throughout relevant committee regarding among audit also matters planned scope timing dentify assess risks material audit significant audit findings including misstatement remuneration report significant deficiencies internal control whether due fraud error design identify audit perform audit procedures responsive risks obtain audit evidence also provide board directors sufficient appropriate provide basis relevant committee statement opinion risk detecting complied relevant ethical requirements material misstatement resulting fraud regarding independence communicate higher one resulting error relationships matters fraud may involve collusion forgery intentional may reasonably thought bear omissions misrepresentations override independence applicable actions internal control taken eliminate threats safeguards applied kpmg ag franois rouiller paul nichols licensed audit expert auditor charge basel january kpmg ag grosspeteranlage ch basel kpmg ag swiss corporation subsidiary kpmg holding ag member kpmg global organisation independent member firms affiliated kpmg international limited private english company limited guarantee rights reservedimprint cautionary statement regarding statement regarding earnings per share growth forwardlooking statements profit forecast interpreted annual report contains certain forwardlooking mean roches earnings earnings per share statements forwardlooking statements may subsequent period necessarily identified words believes expects match exceed historical published earnings anticipates projects intends seeks earnings per share roche estimates future similar expressions discussion among things strategy goals plans trademarks legally protected intentions various factors may cause actual results differ materially future reflected links thirdparty pages provided convenience forwardlooking statements contained annual express opinion content report pricing product initiatives thirdparty pages expressly disclaim competitors legislative regulatory developments liability thirdparty information use economic conditions delay inability thereof obtaining regulatory approvals bringing products market fluctuations currency exchange rates roche annual report published german general financial market conditions uncertainties english discovery development marketing new products new uses existing products including reporting consists actual annual report without limitation negative results clinical trials finance report contains annual financial research projects unexpected side effects pipeline statements consolidated financial statements marketed products increased government pricing pressures interruptions production loss printed nonchlorine bleached fsccertified paper inability obtain adequate protection intellectual property rights litigation loss key executives employees adverse publicity news coveragekey dates annual general meeting march firstquarter sales april halfyear results july ninemonth sales october published f hoffmannla roche ltd group communications basel switzerland tel wwwrochecom orderdownload publications internet wwwrochecompublications email materialsmanagementmmrochecom fax media relations tel email mediarelationsrochecom investor relations tel email investorrelationsrochecom group sustainability email corporatesustainabilityrochecomsharing journey multiple sclerosis antoine helps us improve care people ms since serving patient expert brought valuable perspective roche contributing several significant outcomes read story annual report f hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom